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ABSTRACT 
As growing numbers of students with attention deficit hyperactivity disorder 
(ADHD) pursue postsecondary education, the availability of psychostimulant 
medications on college campuses has steadily increased. Although a large body of 
research has documented that misuse of prescription stimulant medication is a 
prevalent problem on American college campuses, few studies have been conducted 
beyond the United States. Iceland, closely followed by the United States, has the 
highest stimulant medication prescription rates in the world; however, no systematic 
efforts have been made to investigate to what extent these medications are being 
misused within the Icelandic college student population. Therefore, the purpose of the 
present study was to: a) examine the prevalence of prescription stimulant misuse 
among N=521 college students in Iceland as well as factors that are potentially 
predictive of stimulant misuse, including ADHD symptomatology, symptoms of 
depression, anxiety, and stress, self-reported grade-point average (GPA), and student 
sex; and b) identify the prevalence of significant ADHD symptomatology within this 
population. 
Results revealed the prevalence of lifetime stimulant misuse behavior was 
approximately 13% within the overall sample, 11% among participants without a 
prescription for stimulant medication, and 42% among participants holding a 
prescription. The primary reported reason for misuse was academic enhancement, 
similar to findings from the United States and Europe. Findings also suggested risk 
factors for prescription stimulant misuse among college students in Iceland included 
male sex, anxiety symptoms, and a history of ADHD symptoms. Approximately 8% 
  
of participants reported persistent, elevated ADHD symptomatology, while 
approximately 9% reported a previous diagnosis of ADHD.  
The present findings have implications for public health policy in Iceland, 
particularly as it relates to the college population. Limitations of the study and 
suggestions for future research are discussed.
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Introduction 
Attention deficit hyperactivity disorder (ADHD) is a chronic disorder characterized by 
clinically significant levels of inattention, hyperactivity, and impulsivity that causes 
impairment in multiple settings. The disorder is estimated to affect approximately 5% 
of children (Polanczyk, de Lima, Horta, Biederman, & Rohde, 2007) and 2.5% of 
adults (Simon, Czobor, Bálint, Mészáros, & Bitter, 2009) across cultures (American 
Psychiatric Association, 2013). Youth with ADHD often demonstrate various 
problems in the school environment, such as difficulty remaining focused and seated, 
disorganization, talking excessively, as well as noncompliance and aggression 
(Danforth, Connor, & Doerfler, 2014; Pliszka, 2014). Due to these difficulties, 
students with ADHD tend to perform more poorly than their peers academically (e.g., 
receive lower grades, repeat grades, drop out of high school at higher rates, [DuPaul & 
Jimerson, 2014; Faraone et al., 1993]), and are less likely to attend and graduate from 
college (Kuriyan et al., 2013). Despite this poor prognosis, increasing numbers of 
students with ADHD are successfully completing high school and pursuing higher 
education (DuPaul & Weyandt, 2009; Weyandt & DuPaul, 2013). While no definitive 
information is available regarding the prevalence of ADHD in the college population, 
given that the privacy of students with disabilities is protected under the Americans 
with Disabilities Act (1991) and that ADHD may be underdiagnosed among college 
students (Wolf, Simkowitz, & Carlson, 2009), studies estimate that 2-8% of college 
students across cultures have significant ADHD symptoms (DuPaul et al., 2001; 
Eagan et al., 2014; McKee, 2008; Weyandt, Linterman & Rice, 1995), and 
approximately 18%-50% of students who receive disability accommodations in U.S. 
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colleges do so primarily due to ADHD (Raue & Lewis, 2011; Wolf et al., 2009). 
Weyandt and DuPaul (2013), leading researchers in the field, emphasized the paucity 
of information available and stressed the need for studies to explore the prevalence 
and nature of ADHD among college students as well as their academic and social 
functioning. The extant literature has revealed, however, that college students with 
ADHD and elevated ADHD symptomatology tend to exhibit academic 
underachievement (Weyandt et al., 2013a), including lower GPAs (Advokat, Lane, & 
Luo, 2011; Gormley et al., 2015), poorer study habits and study skills (Gormley et al., 
2015), greater difficulty with academic adjustment (Norwalk, Norvilitis, & MacLean, 
2009; Rabiner, Anastopoulos, Costello, Hoyle, & Swartzwelder, 2008; Weyandt et al., 
2013a), and are more likely to drop out of college (Barkley, Murphy, & Fischer, 2008) 
than their non-affected counterparts. College students with ADHD also generally 
report more psychosocial difficulties, including a lower self-esteem (Canu & Carlson, 
2007; Shaw-Zirt, Popali-Lehane, Chaplin, & Bergman, 2005), lower life satisfaction 
(Gudjonsson, Sigurdsson, Eyjolfsdottir, Smari, & Young, 2009), higher levels of 
internalizing and externalizing pathology (e.g., depression, anxiety, and hostility), and 
greater executive dysfunction, compared to students without ADHD (Weyandt et al., 
2013a). More recently, Anastopoulos and colleagues (in press) reported that college 
students with rigorously defined ADHD were significantly more likely than their non-
affected peers to meet diagnostic criteria for one or more comorbid psychiatric 
disorder, particularly depression and anxiety. In fact, 55% of the ADHD participants 
in this study presented with at least one comorbid diagnosis, compared with only 11% 
of the non-ADHD sample. Taken together, this body of research clearly indicates that 
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students with significant ADHD symptoms face numerous challenges during the 
college years. These findings underscore the need for identifying college students with 
attention problems so that effective treatments may be implemented to help promote 
their academic success and well-being. 
Use and Misuse of Prescription Stimulants 
The main treatment options for adults with ADHD include pharmacological 
and psychosocial approaches with stimulant medication commonly recommended as 
part of an individually tailored treatment plan (Kooij et al., 2010; National Institute for 
Health and Clinical Excellence, 2009). Methylphenidate (MPH; e.g., Ritalin, 
Concerta) and amphetamine (AMP; e.g., Adderall, Dexedrine) are the two most 
commonly prescribed stimulants for the treatment of ADHD (Meijer et al., 2009; 
Wilens, 2008), and are similar, although not identical, with respect to their presumed 
neurochemical mode of action. Specifically, research with humans and other animals 
indicates that MPH increases the availability of dopamine in the extracellular space by 
blocking the dopamine transporter, thereby preventing dopamine reuptake (Weyandt, 
2006). Additionally, MPH has been hypothesized to increase norepinephrine 
availability by blocking the norepinephrine transporter (Berridge & Devilbiss, 2011). 
AMP, however, is not only believed to prevent dopamine reuptake, but also to 
stimulate its efflux from the presynaptic neuron, further increasing dopamine 
availability. At higher doses, AMP also appears to stimulate norepinephrine efflux 
(Berridge & Devilbiss, 2011; Weyandt, 2006).  
Although no definitive pathophysiological profile has been documented in 
ADHD, current neurobiological theories posit that catecholaminergic 
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neurotransmission plays an important role (Faraone & Biederman, 1998), particularly 
in the fronto-striatal pathway (Wilens, 2008). Specifically, dysregulation of 
neurotransmission in fronto-subcortical circuits has been associated with problems 
with attention, motor behavior, and executive function, all of which are associated 
with ADHD (although not uniquely so). Treatment with stimulant medication, in turn, 
is believed to enhance catecholaminergic functioning in these areas, as manifested by 
ADHD symptom improvement (del Campo et al., 2013; Engert & Pruessner, 2008; 
Faraone & Biederman, 1998). Previously, prescription stimulants were believed to 
primarily benefit individuals with ADHD; more recent evidence indicates, however, 
these medications may enhance various physiological and cognitive processes in 
individuals without ADHD as well (del Campo et al., 2013; Smith & Farah, 2011).  
Beyond the presumed basic neurochemical actions of prescription stimulants, 
the precise effects of these medications on brain function remain poorly understood. 
Converging evidence supports, however, that when used as prescribed, stimulant 
medications are safe and effective at improving core ADHD symptoms of inattention, 
impulsivity, and hyperactivity, as well as improving psychological, cognitive, and 
social functioning (Adler, Spencer, McGough, Jiang, & Muniz, 2009; Adler et al., 
2013; Brams, Giblin, Gasior, Gao, & Wigal, 2011; DuPaul et al., 2012; Faraone, 
Spencer, Aleardi, Pagano, & Biederman, 2004; Retz et al., 2012; Spencer, Adler, 
Weisler, & Youcha, 2008). Additionally, recent evidence indicates pharmacotherapy 
with stimulants may serve as a protective factor among individuals with ADHD as 
stimulants have been associated with decreased risk of substance abuse (Chang et al., 
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2014; Wilens, Faraone, Biederman, & Gunawardene, 2003) as well as lower risk of 
suicidal behavior (Chen et al., 2014). 
Despite major benefits for individuals with ADHD, prescription stimulants 
also have been associated with more negative outcomes, including a variety of side 
effects (e.g., sleep difficulties, reduced appetite, nausea, abdominal pain, headache, 
and cardiac symptoms [Craig, Davies, Schibuk, Weiss, & Hechtman, 2015; Weyandt 
et al., 2014]) and significant potential for misuse that can possibly lead to 
psychological and/or physiological dependence (Kollins, 2003), as reflected by their 
classification as Schedule II medications by the U.S. Food and Drug Administration 
(2011). As increasing numbers of individuals with ADHD pursue college, the non-
medical use of prescription stimulants has become more evident on college campuses, 
and has been well documented in the literature (Benson, Flory, Humphreys, & Lee, 
2015; Weyandt et al., 2013b). Indeed, many college students claim that stimulant 
medications are easily accessible on campus (McCabe, Knight, Teter & Wechsler, 
2005; Rabiner et al., 2009; Sharp & Rosen, 2007; Weyandt et al., 2009), and 
stimulants are usually obtained from other students with a valid prescription (Benson 
et al., 2015; Weyandt et al., 2013b).  
The non-medical use or misuse of stimulants, usually defined as taking 
stimulants without a valid prescription or greater use of stimulants than as prescribed 
(Benson et al., 2015; Weyandt et al., 2013b), has soared among university students 
since the beginning of the century  (Babcock & Byrne, 2000; DeSantis, Noar, & 
Webb, 2010; DuPont, Coleman, Bucher, & Wilford, 2008; Dussault & Weyandt, 
2013; Hall, Irwin, Bowman, Frankenberger, & Jewett, 2005; Janusis & Weyandt, 
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2010; Judson & Langdon, 2009; Low & Gendaszek, 2002; Messina et al., 2014; 
McCabe et al., 2005; McCabe, West, Teter, & Boyd, 2014; Rabiner et al., 2009; Sharp 
& Rosen, 2007; Verdi, Weyandt, & Zavras, 2014; Weyandt et al., 2009; White, 
Becker-Blease & Grace-Bishop, 2006). For example, Babcock and Byrne reported a 
lifetime prevalence rate of stimulant misuse behavior of 16.6% among college 
students in the year 2000 whereas in 2014 Messina and colleagues reported a lifetime 
prevalence rate of 25.4%. Other studies have reported a lifetime prevalence rate as 
high as 43% (DeSantis, Webb, & Noar, 2008). Recently, Benson and colleagues 
(2015) conducted a meta-analysis of 20 studies in which they estimated the prevalence 
rate of stimulant misuse to be at 17% among college students (95% confidence 
interval [CI] [13%, 23%]). Regardless of exact prevalence rates, studies consistently 
indicate that a large percentage of college students have misused prescription 
stimulants. Given the judicial and potential health risks associated with the misuse of 
prescription stimulants, several studies have attempted to shed light on the motivations 
for engaging in this behavior. 
A systematic review of the literature conducted by Weyandt and colleagues 
(2013) revealed that several reasons for misusing prescription stimulants have been 
reported, chief among them being cognitive and academic enhancement. More 
specifically, college students who disclose engaging in stimulant misuse report doing 
so while studying (e.g., preparing for exams, writing papers) to increase their attention 
and alertness, and thus improve their academic performance. Rabiner and colleagues 
(2009) also found that although a number of reasons for misuse were reported in their 
study, the most strongly endorsed reasons pertained to the enhancement of academic 
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performance. Interestingly, however, stimulant misuse has been found to be negatively 
associated with academic functioning (Benson et al., 2015), which suggests that 
contrary to what students believe, presecription stimulants may not necessarily lead to 
improved academic performance. Weyandt et al. (2013b) as well as Benson et al. 
(2015) reported other less commonly endorsed reasons for the non-medical use of 
stimulants include “getting high”, staying awake to party, extending the effects of 
alcohol or other substances, losing weight, and curiosity, and up to 40% of students 
appear to misuse stimulants for both academic and non-academic reasons (Benson et 
al., 2015). According to Weyandt et al. (2013b), the most common method of 
stimulant administration among those who misuse is oral, followed by intranasal 
administration, but a small percentage of students report either smoking or injecting 
them. Finally, Benson et al. (2015) and Weyandt and colleagues (2013b) reported that 
most students engaging in misuse of prescription stimulants report obtaining the drugs 
from other students, and to a lesser extent from family members; and students have 
also reported stealing the medications from others and overusing their own 
prescriptions. 
To summarize, the misuse of prescription stimulants has increased 
substantially in the past two decades among college students. In addition to examining 
the prevalence, motivations, and characteristics of stimulant misuse, researchers also 
have sought to identify specific predictors of this behavior, including both 
demographic and psychological variables. 
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Predictors of Prescription Stimulant Misuse 
Preliminary studies have identified several demographic variables that are 
predictive of prescription stimulant misuse. For example, results from a number of 
studies have indicated males are more likely to engage in stimulant misuse than 
females, although findings have been inconsistent (Benson et al., 2015; Weyandt et al., 
2013b). Weyandt et al. (2013b) calculated the magnitude of sex differences in studies 
examining the non-medical use of stimulants and found Cohen’s d effect sizes ranging 
from .88 to 5.38, suggesting stark group differences favoring males. In terms of 
race/ethnicity, some studies have found students identifying as white or Caucasian are 
more likely to endorse stimulant misuse than students of non-white backgrounds, 
whereas others have reported no significant differences across racial/ethnic groups 
(Benson et al., 2015). As stated previously, academic performance, usually measured 
by self-reported grade point average (GPA), has been found to be negatively 
associated with misuse of prescription stimulants across several studies (Benson et al., 
2015). For example, Arria, O’Grady, Caldeira, Vincent, and Wish (2008) reported that 
first-year college students who misused prescription stimulants had lower high school 
GPAs, attended classes less frequently, devoted less time to studying, and spent more 
time socializing compared to nonusers. Furthermore, results indicated that past-year 
non-medical use of stimulants predicted lower GPA by the end of the first year of 
college, which was mediated by skipping class. 
With regard to psychological risk factors, depression (Huang et al., 2006; 
Teter, Falone, Cranford, Boyd & McCabe, 2010; Zullig & Divin, 2012), anxiety 
(Dussault & Weyandt, 2013; Verdi et al., 2014; Weyandt et al., 2009), stress (Dussault 
10 
 
& Weyandt, 2013; Peterkin, Crone, Sheridan, & Wise, 2011; Verdi et al., 2014), and 
internal restlessness (Dussault & Weyandt, 2013, Verdi et al., 2014; Weyandt et al., 
2009) have all been found to be predictive of stimulant misuse. Notably, internal 
restlessness has been conceptualized as the adult manifestation of childhood 
hyperactivity; that is, symptoms of physical hyperactivity in childhood are often 
replaced with cognitive, mental, or internal restlessness as individuals enter adulthood 
(Biederman, Mick, & Faraone, 2000; Weyandt et al., 2003). Consequently, some 
researchers have speculated that students who misuse stimulants may be “self-
medicating” to treat symptoms of ADHD. For instance, Rabiner et al. (2009) found 
that ADHD symptoms of inattention significantly predicted misuse of prescription 
stimulants, even after controlling for use of other substances. In contrast, symptoms of 
hyperactivity/impulsivity were associated with greater odds of engaging in other 
substance use. Similarly, Arria and colleagues (2011) found that untreated symptoms 
of inattention were associated with persistent misuse of stimulants. Finally, Benson 
and colleagues’ (2015) meta-analytic review suggested having a diagnosis of ADHD 
is significantly associated with stimulant misuse, with odds ratios ranging from 1.02 to 
21.44. Collectively, these findings suggest ADHD symptoms likely constitute a risk 
factor for stimulant misuse. 
In summary, studies clearly indicate prescription stimulant misuse is a 
prevalent problem on American college campuses. The primary reason students report 
for engaging in such misuse is enhancement of cognitive and academic performance. 
Research, however, presents a different picture, given that misuse of stimulants 
appears to be negatively associated with academic performance, and positively 
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associated with various psychological difficulties, including symptoms of ADHD, 
depression, anxiety, and stress. Preliminary evidence from other countries indicates 
prescription stimulant misuse is not unique to North American college life; however, 
information concerning stimulant misuse behavior among college students in other 
countries is scarce. 
International Studies on Prescription Stimulant Misuse in College 
Studies regarding prescription stimulant misuse beyond the United States are 
scant. An investigation conducted by Deline and colleagues (2014) in Switzerland 
concerning the use of various neuroenhancement drugs, including prescription 
stimulants, among males, revealed that while misuse was much lower than in the 
United States (i.e., 3%), prescription stimulants were the most frequently misused 
drugs. Furthermore, in this sample, college students reported less misuse of 
prescription stimulants than did those not enrolled in college. Surprisingly, Deline et 
al. (2014) did not find an association between ADHD status and misuse behavior; 
however, they identified participants as either ADHD or non-ADHD using a cut-off 
score based only on self-report ratings on a 6-item screening measure. Given the 
limited rigor in Deline et al.’s (2014) assessment of ADHD symptoms the validity of 
these findings is equivocal. Maier, Liechti, Herzig, and Schaub (2013) also 
investigated stimulant misuse in Switzerland among over 6,000 university students of 
whom 4.5% endorsed having used either MPH or AMP, primarily for academic and/or 
cognitive enhancement. In this study, students who reported increased levels of stress 
were significantly more likely to endorse misuse behavior, mirroring findings from the 
United States linking psychological distress with stimulant misuse (e.g., Benson et al., 
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2015; Weyandt et al., 2009). A study by Mache, Eickenhorst, Vitzthum, Klapp, and 
Groneberg (2012) regarding substance use among German university students 
revealed that approximately 1-13% had used either prescription stimulants or illicit 
psychoactive drugs (e.g., cannabis) at least once. Similar to American students, the 
main reported motives for using these drugs were to improve concentration, increase 
alertness, and relax. In another German study, Dietz and colleagues (2013) examined 
the 12-month prevalence of the use of cognitive enhancement drugs among university 
students, including amphetamines, caffeine tablets, cocaine, methylphenidate, and 
mephedrone. Results suggested 20% of the students had used cognitive enhancers 
within the past 12 months and that males were more likely than females to have used 
such drugs.  
The results of these studies indicate that European university students are 
indeed using various substances, including prescription stimulants, to ostensibly 
improve their attention and academic performance, much like their American 
counterparts. Preliminary studies suggest the prevalence of misuse behavior in these 
countries may be lower than in the United States; however, more detailed information 
regarding this issue is needed. 
Use of Prescription Stimulants in Iceland 
Although limited data exist regarding misuse of prescription stimulants among 
college students beyond the United States, research indicates that in terms of 
prescription rates, Iceland, closely followed by the United States, has the highest per 
capita overall consumption of prescription stimulants in the world among children, 
adolescents, and adults, or 8-12 defined daily doses for statistical purposes (S-DDD), 
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compared with 2-6 S-DDD in Canada, Switzerland, Sweden, and Norway, for example 
(Kaye & Darke, 2012). Similarly, Zoëga and colleagues’ (2011) investigation of 
stimulant use in the Nordic countries revealed the rate of prescriptions for stimulant 
medications in Iceland was nearly 12 times that in Finland and almost five times that 
in Sweden. Moreover, using data from the complete nationwide drug prescription 
database in Iceland, Geirs, Pottegård, Halldórsson, and Zoëga (2014) reported the 1-
year period prevalence of overall prescription stimulant use tripled between 2003 and 
2012, with the largest increases in prescription rates among young adults between the 
ages of 19 and 24. No studies have been conducted to date, however, to specifically 
examine the prevalence of ADHD in the Icelandic population. Despite widespread use 
of ADHD medications in Iceland, only one study that examined prescription stimulant 
misuse in Iceland was found, and included a group of individuals with chronic 
substance abuse problems who used these medications mostly intravenously 
(Bjarnadottir et al., 2013). Bjarnadottir and colleagues (2013) concluded that 
prescription stimulant misuse is a growing problem in Iceland, at least among those 
with addiction issues. In addition, the International Narcotics Control Board (INCB) 
requested clarification from Icelandic authorities due to the high rates of stimulant 
prescriptions to children, adolescents, and adults (The Icelandic Medical Journal, 
2011).  
Given the similarities between Iceland and the United States with respect to 
stimulant prescription rates, the growing numbers of young adults prescribed stimulant 
medications in Iceland, and the prevalence of stimulant misuse on American college 
campuses, it is highly plausible these medications are also being misused among 
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Icelandic college students. To date, however, no systematic efforts have been made to 
evaluate the scope and nature of prescription stimulant misuse among college students 
in Iceland, nor how the prevalence of ADHD symptomatology in this population 
relates to such behavior. In light of the health and judicial risks associated with misuse 
of prescription stimulants, it is critical to investigate the extent to which these 
medications are being misused in Iceland as well as factors, such as ADHD 
symptomatology, that are predictive of prescription stimulant misuse. 
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Purpose of the Study 
A voluminous body of research has assessed the prevalence, characteristics, 
and predictors of prescription stimulant misuse among undergraduate students in the 
United States. The results of these studies collectively indicate this behavior 
constitutes a significant problem on American college campuses (Benson et al., 2015; 
Weyandt et al., 2013b). Only a few studies, however, have assessed the prevalence of 
prescription stimulant misuse beyond the United States. Prescription rates for 
stimulant medications for ADHD are similar in Iceland and the United States; 
however, in contrast to the United States, no studies have been conducted to assess the 
prevalence of prescription stimulant misuse among college students in Iceland. 
Therefore, the purpose of the present study was to explore the prevalence rates of 
prescription stimulant misuse among Icelandic college students and to examine 
potential predictors of this behavior. Such findings will be instrumental in the 
development of prevention and intervention programs to help improve the outcomes of 
college students who misuse prescription stimulants. For the purposes of the present 
study, prescription stimulant misuse was defined as use of stimulant medications 
without a valid prescription (e.g., Dussault & Weyandt, 2013; Verdi et al., 2014). 
Specifically, the current study investigated: a) self-reported prevalence of prescription 
stimulant misuse among Icelandic college students, and b) self-reported prevalence of 
ADHD symptomatology as well as symptoms of depression, anxiety, and stress. 
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Research Hypotheses 
Based on previous empirical findings, it was hypothesized that:  
1) Male sex would be more strongly associated with prescription stimulant 
misuse behavior than female sex, 
2) Self-reported GPA would be negatively associated with prescription 
stimulant misuse, 
3) Symptoms of depression, anxiety, and stress would be positively associated 
with prescription stimulant misuse, and 
4) ADHD symptomatology would significantly predict prescription stimulant 
misuse while controlling for symptoms of depression, anxiety, and stress.  
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Method 
Procedure 
The current study was approved by the National Bioethics Committee of 
Iceland (reference number: VSNb2014050018/03.07) as well as the Institutional 
Review Board (IRB) at the University of Rhode Island. University staff and faculty at 
four universities in Iceland were contacted via email, and asked to assist with the 
recruitment of undergraduate research participants. Two of the universities were 
located in the capital region of Iceland, whereas the other two were located in more 
rural areas. Specifically, contact people at each of the four universities were asked to 
forward an email containing a brief summary of the study and a link to a secure online 
survey website (SurveyMonkey) to all Icelandic undergraduate students who might be 
eligible and willing to participate. To further facilitate participant recruitment, the 
same information was posted on public Icelandic Facebook webpages. Before 
initiating the online survey, potential participants were presented with an electronic 
informed consent form (Appendix A) and instructed to confirm they had read and 
understood the content by checking a statement of endorsement. The consent form 
contained the researchers’ contact information should participants have had questions 
or concerns and listed the requirements and responsibilities of participating in the 
study, including a description of the research project (e.g., time commitment, potential 
for harm, anonymity, etc.). Participants were made aware that the survey was 
completely voluntary and anonymous and that they had the opportunity to discontinue 
participation in the study at any time. Participants who provided consent to participate 
were then directed to the study questionnaires. To encourage participation, potential 
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participants were offered to enter a drawing at the end of the survey for a chance to 
win a 5,000 ISK gift card (≈45 USD). Upon completion of the study questionnaires, 
participants were debriefed and provided with information regarding how to contact 
the researchers with any questions or concerns (see Appendix B). 
Participants 
A total of 931 individuals accessed the online survey; 929 agreed to participate 
while 2 individuals declined participation. The present sample included N=521 
participants of undergraduate status from the four largest universities in Iceland, n=34 
of whom (6.5%) reported having a current prescription for psychostimulant 
medication. The remaining 408 participants reported being of graduate student status 
(n=102), did not disclose their status, and/or did not complete the entire survey 
(n=306). Participants holding a current prescription for stimulant medication were 
excluded from regression analyses concerning predictors of stimulant misuse 
behavior, given the current study’s definition of misuse as use of stimulants without a 
valid prescription. This subgroup of participants, however, was not excluded from 
other analyses (e.g., psychometric analyses, prevalence rates of stimulant misuse 
[although stimulant misuse prevalence rates were calculated separately for each group 
based on prescription status], and prevalence of significant ADHD symptomatology 
calculations). 
The mean age of participants was 28.33 years (SD=8.36; range 19-57 years). A 
majority of participants identified as female (81.4%), and 18.6% identified as male. 
Based on available demographic information (Reykjavik University 2011; University 
of Iceland, 2013), approximately 60% of participants were expected to be female; 
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therefore, the gender distribution of the current sample was more unequal than 
anticipated. As expected, a large majority of participants identified as white (99.2%), 
compared with only 0.8% identifying as either non-white or other. Sixty-nine 
participants (13.2%) endorsed having some form of a disability and 47 participants 
(9%) reported a previous diagnosis of ADHD. Information concerning participant 
demographics can be found in Table 1 and a statement regarding diversity in research 
is presented in Appendix C.  
Measures 
Demographics Questionnaire. The demographics questionnaire included 
questions about participant age, gender/sex, race/ethnicity, university, degree program, 
cumulative grade point average (GPA), ADHD diagnostic status, and stimulant 
medication prescription status. As stated previously, participants who reported having 
a current prescription for stimulant medication were not excluded from participating in 
the study but for regression analyses concerning stimulant misuse behavior their 
responses were not included, given that the focus of the study was use of prescription 
stimulants without a valid prescription. The demographic questionnaire is presented in 
Appendix D. 
DSM-IV Checklist of Symptoms.The DSM-IV Checklist of Symptoms 
comprises 18 statements regarding symptoms of ADHD based on DSM-IV criteria 
(APA, 1994), nine of which pertain to each symptom domain of inattention and 
hyperactivity/impulsivity, respectively. Each statement is rated in terms of its 
frequency of occurrence (0 = never, 1 = sometimes, 2 = often, 3 = very often). 
Participants were asked to rate both current (preceding 6 months) and childhood (prior 
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to the age of 12) symptom frequency. Magnússon et al. (2006) reported that the 
Icelandic version of the DSM-IV Checklist of Symptoms demonstrated “excellent” (p. 
501) reliability and validity in their sample, including strong correlations with well-
defined childhood and adulthood ADHD. The DSM-IV Checklist of Symptoms is 
presented in Appendix E. 
The Depression Anxiety Stress Scale -21 (DASS-21). The DASS-21 (Lovibond 
& Lovibond, 1995) comprises 21 items measuring levels of anxiety, depression and 
stress among adults. Responses are provided on a 4-point Likert-scale to express the 
extent to which each statement has applied to the respondent during the previous seven 
days.  Response options range from 0 to 3 (i.e., “did not apply to me at all” to 
“applied to me very much/most of the time”; Lovibond & Lovibond, 1995). An 
Icelandic version of the DASS-21 was used in the current study. Gudjonsson et al. 
(2009) reported excellent internal consistency coefficients for the Icelandic version of 
the DASS-21 in a sample of college students, with Cronbach’s alpha for the three 
subscales and total score ranging between 0.86-0.95. Additionally, Ingimarsson (2010) 
reported that the DASS-21 had acceptable convergent and discriminant validity. The 
DASS-21 is presented in Appendix F. 
Stimulant Survey Questionnaire-I (SSQ-I).The SSQ-I contains 40 items 
(Weyandt et al., 2009) designed to assess misuse of prescription stimulants among 
college students, as well as perceptions of and knowledge about prescription stimulant 
use. Thirty items are statements to which participants respond on a 5-point Likert scale 
(e.g., “never” to “always” or “strongly disagree” to “strongly agree”, as applicable). 
Response options are presented in dichotomous format for the final 10 items (“yes” or 
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“no”). For the original version of SSQ-I, a total score can be obtained by summing the 
items although items also have been observed to load on four distinct factors: (1) Self-
reported prescription stimulant use, (2) Perception of prevalence of prescription 
stimulant use among peers, (3) Knowledge of atypical stimulant use among peers, and 
(4) Perception of safety of stimulants (Weyandt et al., 2009). For the purposes of the 
present study, an Icelandic translation of the SSQ was administered; given the lack of 
information pertaining to its reliability, validity, and dimensionality, psychometric 
analyses were conducted. The SSQ is presented in Appendix G. 
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Results 
Data Analyses 
Preliminary psychometric analyses were conducted, including an assessment of 
the internal consistency of each measure, as well as the factor structure of the newly 
translated Icelandic version of the SSQ. Additionally, data were examined with regard 
to assumptions of normality, linearity, and homoscedasticity. Prevalence rates of 
stimulant misuse were assessed by calculating the percentage of students who 
endorsed at least one form of prescription stimulant misuse behavior as having 
occurred at least “rarely”, as measured by the Use of Stimulants for Academic, 
Cognitive, Physical, or Social Enhancement, and Use of Stimulants for Partying or 
Getting High components of the Icelandic version of the SSQ. The prevalence of 
significant ADHD symptomatology was assessed by calculating the percentage of 
students who earned total scores of at least 25 and 23 on the childhood and adulthood 
versions of the DSM Checklist of Symptoms, respectively. Magnússon et al. (2006) 
reported these cutoff scores have a sensitivity index of 0.80 and specificity of 0.90 for 
detecting ADHD in childhood as well as adulthood.  
Hypothesis 1, that male sex (independent variable; IV) would be more strongly 
associated with prescription stimulant misuse than female sex, as measured by the Use 
of Stimulants for Academic, Cognitive, Physical, or Social Enhancement and Use of 
Stimulants for Partying or Getting High components of the Icelandic version of the 
SSQ (dependent variables; DV), was tested via simple regression. 
Hypothesis 2, that self-reported GPA (IV) would be negatively associated with 
prescription stimulant misuse, as measured by the Use of Stimulants for Academic, 
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Cognitive, Physical, or Social Enhancement and Use of Stimulants for Partying or 
Getting High components of the Icelandic version of the SSQ (DV), was tested via 
simple regression. 
Hypothesis 3, that symptoms of depression, anxiety, and stress as measured by 
the three corresponding subscales of the DASS-21 (IVs), respectively, would be 
positively associated with prescription stimulant misuse, as measured by the Use of 
Stimulants for Academic, Cognitive, Physical, or Social Enhancement and Use of 
Stimulants for Partying or Getting High components of the Icelandic version of the 
SSQ (DV), was tested via multiple regression. 
Hypothesis 4, that symptoms of ADHD, as measured by scores on the DSM-IV 
Checklist of Symptoms (IVs), would significantly predict prescription stimulant 
misuse as measured by the Use of Stimulants for Academic, Cognitive, Physical, or 
Social Enhancement and Use of Stimulants for Partying or Getting High components 
of the Icelandic version of the SSQ (DV), while controlling for symptoms of 
depression, anxiety, and stress (IVs), as measured by the three corresponding 
subscales of the DASS-21 respectively, was tested using multiple regression. 
Other analyses included examining differences in prescription stimulant 
misuse between students with and without a prescription for stimulant medication 
(descriptively), group differences in scores on the DASS-21 and DSM-IV Checklist of 
Symptoms based on history of stimulant misuse, and group differences in scores on 
the DASS-21 and SSQ based on significant ADHD symptomatology status as well as 
self-reported disability status. Based on the results of a post hoc power analysis 
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conducted in G*Power 3.2.1 (Faul, Erdfelder, Buchner, & Lang, 2009), the current 
study had estimated power ranging between 0.72 – 0.99, depending on analysis. 
Missing Data 
At the individual item level, missing data ranged between 0.2% and 6%. As for 
missing data patterns, the percentage of missing data was generally lower for items 
administered earlier in the survey (e.g., the SSQ) compared to items administered later 
in the survey (e.g., DASS-21, DSM-IV Checklist of Symptoms, Demographic 
Questionnaire). Although no universal agreement exists concerning what percentage 
of missing data should be regarded as problematic, estimates have ranged between 5-
20% (Schlomer, Bauman, & Card, 2010). Missing data were handled using listwise 
deletion. 
Psychometric Analyses 
Icelandic Translation of the SSQ. An exploratory principal components 
analysis (PCA) of the Icelandic translation of the SSQ with Varimax rotation was 
conducted. Responses from all participants, regardless of prescription status, were 
included to obtain as large a sample as possible. It should be noted that items 35 and 
36 of the original version of the SSQ were combined into a single item as their 
meaning and content was virtually identical in the Icelandic translation. The Icelandic 
version of the SSQ therefore included a total of 39 items, as opposed to 40. 
Additionally, it should be noted that item 5 of the Icelandic version of the SSQ, 
concerning injection of prescription stimulants, was impossible to include in the PCA 
given that every participant endorsed this item as never having occurred (i.e., as “0”). 
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Velicer’s MAP test and Horn’s parallel analysis were used to determine the 
number of components (O’Connor, 2000), both of which suggested 8 components 
should be extracted. The PCA (see table 2) revealed items 1, 6, 9, 19, 20, 38, and 39 
had complex loadings; however, items 1, 6, 9, and 38 were retained given that they fit 
well conceptually with at least one of the components on which they loaded. Although 
items 19, 20, and 39 were not eliminated from the overall scale, they were not added 
to any of the components identified by the PCA. Component 8 comprised three of the 
complex items 6, 19, and 38, all of which were either added to other components due 
to better conceptual fit, or excluded. Therefore, the eighth component was eliminated, 
resulting in a total of 7 components. Another PCA with 7 components, excluding 
items 5, 19, 20, and 39, was conducted (see table 3). Table 4 depicts the eigenvalues 
and percentage of variance explained for each component. 
Items 1, 9, and 10 were complex and loaded on components 1 and 2. Despite 
their complexity, all three items were retained due to their importance in assessing 
stimulant misuse behavior; item 1 was added to component 2 and items 9 and 10 to 
component 1, due to higher component loadings and better conceptual fit. Similarly, 
items 15 and 16 were also complex; however, they were both retained and added to 
component 6 for optimal conceptual fit. 
The overall internal consistency coefficient for all 39 items of the SSQ was 
Cronbach’s alpha = 0.741. The 7 components were conceptualized and labeled as 
follows:  
1. Use of Stimulants for Academic, Cognitive, Physical, or Social Enhancement 
(Cronbach’s alpha = .905);  
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2. Use of Stimulants for Partying or Getting High (Cronbach’s alpha = 0.896); 
3. Knowledge of Other Students’ Use of Stimulants (Cronbach’s alpha = 0.856); 
4. Perceptions of Stimulant Availability (Cronbach’s alpha = .783); 
5. Perceptions of Stimulant Safety (Cronbach’s alpha = 0.774); 
6. Sharing Stimulants with Other Students (Cronbach’s alpha = 0.563); and  
7. Perceived Knowledge about Stimulants (Cronbach’s alpha = 0.945). 
All internal consistency coefficients for the SSQ as a whole, as well as its 7 
components, ranged from acceptable to excellent with the exception of component 6, 
Sharing Stimulants with Other Students (alpha = 0.563) which may partly stem from 
relatively low component loadings for 2 out of the 4 items contributing to this 
component, as illustrated in table 3. Together, the 7 components accounted for 65.4% 
of the overall variance (see table 4).  
Intercorrelational analyses for the 7 components of the SSQ, presented in table 
5, revealed Use of Stimulants for Academic, Cognitive, Physical, or Social 
Enhancement and Use of Stimulants for Partying or Getting High were significantly 
and positively correlated (r = 0.52, p < 0.001). Additionally, Sharing Stimulants with 
Other Students was significantly correlated with Use of Stimulants for Academic, 
Cognitive, Physical, or Social Enhancement (r = 0.46, p < 0.001) and Use of 
Stimulants for Partying or Getting High (r = 0.42, p < 0.001). Perceptions of Stimulant 
Safety were significantly but modestly correlated with Use of Stimulants for 
Academic, Cognitive, Physical, or Social Enhancement (r = 0.19, p < 0.001) as well as 
Use of Stimulants for Partying or Getting High (r = 0.13, p = 0.004). Similarly, 
Perceived Knowledge about Stimulants was only modestly correlated with Use of 
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Stimulants for Academic, Cognitive, Physical, or Social Enhancement (r = 0.15, p = 
0.001), but not Use of Stimulants for Partying or Getting High (r = 0.07, p = 0.11). 
DASS-21 and DSM-IV Checklists of Symptoms. The Cronbach’s alphas for the 
three subscales of the DASS-21 as well as the DASS-21 as a whole were excellent: 
Depression = 0.921, Anxiety = 0.833, Stress = 0.873, DASS-21-Total = 0.942. In a 
similar vein, the Cronbach’s alphas for the subscales and total score of the DSM 
Checklist of Symptoms were excellent: Inattention Past 6 Months = 0.893, 
Hyperactivity/Impulsivity Past 6 Months = 0.826, ADHD Total Past 6 Months = 
0.913; Inattention Childhood = 0.936, Hyperactivity/Impulsivity Childhood = 0.931, 
ADHD Total Childhood = 0.958. 
Prevalence of Prescription Stimulant Misuse Behavior 
Overall prevalence of lifetime prescription stimulant misuse, irrespective of 
prescription status, was 13.2% (95% CI: [10.26%, 16.14%]). Specifically, lifetime 
prevalence of a score of 1 or higher on Use of Stimulants for Academic, Cognitive, 
Physical, or Social Enhancement was 10.1% (95% CI: [7.5%, 12.7%]) while 
prevalence of a score of 1 or higher on Use of Stimulants for Partying or Getting High 
was 10.9% (95% CI: [8.21%, 13.59%]). 
Among those without a current prescription for prescription stimulant 
medication, the overall prevalence of lifetime prescription stimulant misuse was 
11.2% (95% CI: [8.34%, 14.06%]). The percentage of participants earning a score of 
at least 1 or higher on the Use of Stimulants for Academic, Cognitive, Physical, or 
Social Enhancement component of the SSQ was 8.1% (95% CI: [5.64%, 10.56%]). 
With regard to the Use of Stimulants for Partying or Getting High component, the 
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percentage of participants earning a score of at least 1 or higher was 10.2% (95% CI: 
[7.47%, 12.93%]). Within the group of participants holding a current prescription, the 
overall prevalence of lifetime prescription stimulant misuse was 42.4% (95% CI: 
[25.79%, 59.01%]) The percentage of participants with a prescription earning a score 
of at least 1 or higher on the Use of Stimulants for Academic, Cognitive, Physical, or 
Social Enhancement component of the SSQ was 42.4% (95% CI: [25.79%, 59.01%]). 
As for the Use of Stimulants for Partying or Getting High subscale, the percentage of 
participants with a prescription earning a score of at least 1 or higher was 10.2% (95% 
CI: [0.03%, 20.37%]). 
Table 6 provides prevalence rates for each individual stimulant misuse 
behavior, broken down by prescription status. As table 6 illustrates, the prevalence of 
stimulant misuse behavior was generally higher among those currently holding a 
prescription for stimulants compared to those without a prescription. An important 
caveat, however, is the fact that the group currently holding a prescription for 
stimulant medication was significantly smaller (n=34) than the group without a 
prescription (n=487). Interestingly, 7.7% of the entire sample reported having been 
offered prescription stimulants by other students; within the group without a current 
prescription only 6.7% endorsed having been offered prescription stimulants by other 
students whereas 17.6% of the group currently holding a prescription had been offered 
such drugs by peers. Overall, the most commonly endorsed reasons for misusing 
stimulants were to 1) perform better in schoolwork, 2) feel more energetic, 3) perform 
better on tests, 4) focus better in class, and 5) to “get high”. In the group without a 
prescription the most commonly endorsed reasons for misuse were as follows: to 1) 
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perform better in schoolwork, 2) feel more energetic, 3) “get high”, 4) perform better 
on tests, and 5) focus better in class. Within the group currently holding a prescription 
the following reasons emerged as the most commonly endorsed: to 1) perform better 
in schoolwork, 2) perform better on tests, 3) focus better in class/feel more energetic, 
4), socialize better, and 5) feel better about myself.  
As can be seen in table 7, a small percentage (11-12%) of participants agreed 
or strongly agreed that stimulants are easily accessible, regardless of prescription 
status. The percentage of participants without a prescription agreeing or strongly 
agreeing that stimulant use on campus is a problem was 14.5% while for participants 
holding a prescription it was 8.8%. The group without a prescription generally felt 
either neutral or disagreed that occasional or daily use of stimulants is harmless (7.4% 
agreed or strongly agreed that occasional use is harmless; 1.9% agreed or strongly 
agreed that daily use is harmless). In the group currently holding a prescription for 
stimulant medication the percentage of participants agreeing or strongly agreeing that 
such use is harmless was much higher (32.4% agreed or strongly agreed that 
occasional use is harmless; 17.6% agreed or strongly agreed that daily use is 
harmless).  
Also evident from data presented in table 7, a considerable percentage of 
students reported feeling knowledgeable about stimulants and their side effects, and 
within the group holding a current prescription this percentage was approximately 
double that of the group without a prescription (42% and 41.3% in the group without a 
prescription compared with 76.5% and 85.3%, in the group with a prescription). 
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Table 8 illustrates the percentage of participants who agreed to statements 
regarding prescription stimulant misuse. A large majority of students endorsed 
knowing about other students who use stimulants for academic, cognitive, and 
physical enhancement, as well as for recreational reasons (74% - 96% in the overall 
group). Of students holding a prescription for stimulants, 55% reported hiding their 
medication to prevent others from taking it. 
Group Differences based on History of Stimulant Misuse 
Table 9 includes the minimum and maximum values as well as the means and 
standard deviations for each of the components/subscales of the SSQ, DASS-21, and 
DSM-IV Checklist of Symptoms broken down by history of stimulant misuse among 
participants without a current prescription for stimulant medication. Based on 
descriptive data, all component/subscale means were higher in the group reporting a 
history of stimulant misuse (i.e., among students earning a score of at least 1 on the 
Use of Stimulants for Academic, Cognitive, Physical, or Social Enhancement or Use 
of Stimulants for Partying or Getting High components of the SSQ), except for the 
Knowledge of Other Students’ Use of Stimulants component of the SSQ. Independent 
samples t-tests, also illustrated in table 9, revealed scores on the Knowledge of Other 
Students’ Use of Stimulants were significantly higher in the group without a history of 
stimulant misuse with Cohen’s d in the large range (Cohen, 1992). Perceptions of 
Stimulant Safety, Sharing Stimulants with Other Students, Perceived Knowledge 
about Stimulants, past 6-month ADHD total score, and childhood ADHD total, score, 
however, were all significantly higher in the group reporting a history of stimulant 
misuse, with Cohen’s d effect sizes ranging from small to large (Cohen, 1992). In 
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contrast, no significant differences were found for any of the DASS-21 subscales of 
depression, anxiety, or stress. Findings should be interpreted with caution, however, 
due to significantly different variances across groups in some cases (see table 9). 
Additionally, because these analyses were simply exploratory in nature and conducted 
post-hoc, no multiple comparison corrections (e.g., Bonferroni) were made (see 
Armstrong, 2014). 
Factors Predictive of Prescription Stimulant Misuse 
For each of the regression models, errors were examined with regard to 
assumptions of linearity, normality, and homoscedasticity, as depicted in figures 1-24. 
Results should be interpreted cautiously given that assumptions of normality and 
homoscedasticity may not have been met, possibly due in part to considerable zero-
inflation and hence positive skewness in the dependent variable (see figures 25 and 
26). As stated previously, participants holding a current prescription for stimulant 
medication were excluded from the regression analyses given the present study’s 
definition of stimulant misuse as use of stimulants without a valid prescription. 
Prior to conducting regression analyses, preliminary intercorrelational analyses 
between all independent and dependent variables were performed. Results, delineated 
in table 10, revealed Use of Stimulants for Academic, Cognitive, Physical, and Social 
Enhancement was significantly and positively correlated with DASS-21 anxiety scores 
(r = 0.195, p < 0.001) and childhood total ADHD score (r = 0.216, p < 0.001). Use of 
Stimulants for Partying or Getting High was positively and significantly correlated 
with participant sex (r = 0.147, p < 0.04; male sex was associated with greater use), 
and with past 6-month total ADHD score (r = 0.105, p < 0.043) childhood total 
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ADHD score (r = 0.200, p < 0.001). Neither Use of Stimulants for Academic, 
Cognitive, Physical, and Social Enhancement nor Use of Stimulants for Partying or 
Getting High was associated with DASS-21 depressive symptoms, DASS-21 stress 
symptoms, or GPA. Also of note is that all DASS-21 subscales, depression, anxiety, 
and stress, were significantly intercorrelated. ADHD childhood total score was 
significantly correlated with ADHD past 6 month total score: r = 0.729, p < 0.001, and 
ADHD total scores in both childhood and adulthood were significantly correlated with 
all DASS-21 subscales (i.e., depression, anxiety, and stress). 
Among participants without a current prescription for stimulant medication, 
the first hypothesis, that male sex would be more strongly associated with prescription 
stimulant misuse than female sex, was partially supported. Although sex did not 
significantly predict Use of Stimulants for Academic, Cognitive, Physical, or Social 
Enhancement (see table 11), sex significantly predicted Use of Stimulants for Partying 
or Getting High (see table 12), with males being more likely to report such behavior. 
Sex, however, only explained 1% in the variance of the dependent variable.  
The second hypothesis, that self-reported GPA would be negatively associated 
with prescription stimulant misuse, was neither supported for Use of Stimulants for 
Use of Stimulants for Partying or Getting High (see table 11) nor for Use of 
Stimulants for Academic, Cognitive, Physical, or Social Enhancement (see table 12). 
The third hypothesis, that symptoms of depression, anxiety, and stress would 
be positively associated with prescription stimulant misuse was partially supported. 
Anxiety, but not depression or stress, was significantly and positively associated with 
Use of Stimulants for Academic, Cognitive, Physical, or Social Enhancement (see 
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table 11). The model explained approximately 4% of the variance in the dependent 
variable; hence, the effect size was small. Symptoms of depression, anxiety, and 
stress, however, did not significantly predict Use of Stimulants for Partying or Getting 
High (see table 12).  
The fourth hypothesis, that ADHD symptoms would significantly predict 
prescription stimulant misuse while controlling for symptoms of depression, anxiety, 
and stress was supported. Both childhood and past 6 months’ symptoms of ADHD 
significantly predicted Use of Stimulants for Academic, Cognitive, Physical, or Social 
Enhancement. The model explained 9% of the variance in the dependent variable; thus 
the effect size was small. Of note, however, is that the relationship between childhood 
ADHD symptoms and stimulant misuse was positive whereas for past 6 months’ 
ADHD symptoms it was negative. With regard to Use of Stimulants for Partying or 
Getting High, only childhood symptoms of ADHD emerged as a significant predictor. 
The latter model explained 4% of the variance in the dependent variable. 
Prevalence of Significant ADHD Symptomatology 
Within the entire sample, regardless of prescription status, the percentage of 
students reporting current (past 6-months) significant ADHD symptomatology (i.e., 
obtaining a total score of 23) on the DSM Checklist of Symptoms was 10.7% (95% 
CI: [7.95%, 13.45%]), and the percentage of students reporting significant childhood 
ADHD symptomatology (i.e., obtaining a total score of 25) was 15.2% (95% CI: 
[12.01%, 18.39%]). The percentage of participants from the entire sample reporting 
significant ADHD symptomatology on the DSM-IV Checklist of Symptoms, both 
currently (past 6 months) and in childhood was 8.0% (95% CI: [5.52%, 10.48%]), 
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compared with 9.1% of participants endorsing having been diagnosed previously with 
ADHD at some point in their lifetime (95% CI: [6.62%, 11.58%]). Of those reporting 
having been diagnosed previously with ADHD, 47.83% endorsed the ADHD-
Inattentive subtype, 2.17% endorsed the ADHD-Hyperactive/Impulsive subtype, and 
36.96% endorsed the ADHD-Combined subtype, while 13.04% reported not knowing 
the subtype with which they had been diagnosed. The correlation between significant 
ADHD symptomatology as defined in the present study, and a self-reported, previous 
ADHD diagnosis was statistically significant: r = 0.42, p < 0.01. Approximately 38% 
of participants with significant ADHD symptoms reported a previous diagnosis of 
ADHD, compared with about 6% of participants without significant ADHD 
symptoms. Among participants reporting a previous diagnosis of ADHD, only 35% 
were classified as having significant ADHD symptoms, based on the present study’s 
definition. 
Within the group of participants meeting criteria for significant ADHD 
symptomatology as defined in the present study, approximately 20% endorsed having 
a current prescription for stimulant medication, compared with 4.5% of those not 
meeting criteria for significant ADHD symptomatology. Of those participants who 
reported a previous ADHD diagnosis, 59.6% endorsed being prescribed stimulant 
medication. 
Also of interest were potential group differences based on significant ADHD 
symptomatology group status. Participants with significant ADHD symptomatology in 
both childhood and adulthood, regardless of prescription status, reported greater levels 
of depression (t(416) = 2.96, p = 0.006; Cohen’s d = 0.84), anxiety (t(416) = 2.80, p = 
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0.009; Cohen’s d = 0.85), and stress (t(416) = 2.45, p = 0.02; Cohen’s d = 0.57) 
relative to those without significant ADHD symptoms, as defined in the present study. 
Cohen’s d effect sizes were in the medium to large range; however, results should be 
interpreted cautiously as the homogeneity of variance assumption may not have been 
met. Regarding Use of Stimulants for Academic, Cognitive, Physical, or Social 
Enhancement (t(449) = 1.41, p = 0.16) as well as Use of Stimulants for Partying or 
Getting High (t(449) = 0.497, p = 0.62), irrespective of prescription status, no 
statistically significant group differences were found. Similarly, when those with a 
current prescription for stimulant medication were excluded from the analyses, 
participants with significant ADHD symptoms did not report significantly greater Use 
of Stimulants for Academic, Cognitive, Physical, or Social Enhancement (t(419) = -
0.97, p = 0.34) or Use of Stimulants for Partying or Getting High (t(419) = -0.86, p = 
0.40) than those without significant ADHD symptoms. Importantly, given that group 
differences analyses based on ADHD symptomatology were exploratory in nature and 
conducted post hoc, no corrections were made for multiple comparisons (see 
Armstrong, 2014). 
Additional Post Hoc Analyses 
Among participants without a current prescription for stimulant medication, 
independent t-tests indicated those reporting a disability did not report significantly 
more stimulant misuse for academic, cognitive or other enhancement (t(413) = -1.63, 
p = 0.11) or for recreational reasons (t(413) = -1.20, p = 0.24) than participants not 
reporting a disability. Variances were not equal across the two groups; therefore, 
results should be interpreted with caution. In contrast, significant group differences 
36 
 
were found for all subscales of the DASS-21; participants with a disability reported 
significantly higher depression (t(413) = -2.89, p = 0.005), anxiety (t(413) = -3.63, p = 
0.001), and stress (t(413) = -3.48, p = 0.001) than participants without a disability. 
The same pattern of results emerged when participants holding a current 
prescription for stimulant medication were included in the analyses: Use of Stimulants 
for Academic, Cognitive, Physical, or Social Enhancement: (t(449) = -1.71, p = 0.09), 
Use of Stimulants for Partying or Getting High: (t(449) = -1.16, p = 0.25), DASS-21 
depression (t(449) = -3.62, p = 0.001), DASS-21 anxiety (t(449) = -4.10, p < 0.001), 
and DASS-21 stress (t(449) = -4.15, p < 0.001) were not significant across the two 
groups. 
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Discussion 
The present study was the first to examine prevalence rates of prescription 
stimulant misuse among college students in Iceland and its relation to student sex, 
GPA, psychological symptoms of depression, anxiety, and stress, as well as ADHD 
symptoms. Further, the current study sought to identify the prevalence of significant 
ADHD symptomatology within this population. Specifically, it was hypothesized that: 
1) male sex would be more strongly associated with prescription stimulant misuse than 
female sex; 2) self-reported GPA would be negatively associated with prescription 
stimulant misuse; 3) symptoms of depression, anxiety, and stress would be positively 
associated with prescription stimulant misuse; and 4) ADHD symptomatology would 
significantly predict prescription stimulant misuse while controlling for symptoms of 
depression, anxiety, and stress. In addition, psychometric analyses were conducted for 
the newly translated Icelandic version of the SSQ. 
Psychometric Findings 
Results revealed the underlying component structure of the Icelandic version 
of the SSQ was different from that of the original four factor version (Weyandt et al., 
2009); in the present sample, items were observed to load on seven distinct 
components, named: a) Use of Stimulants for Academic, Cognitive, Physical, or 
Social Enhancement; b) Use of Stimulants for Partying or Getting High; c) Knowledge 
of Other Students’ Use of Stimulants; d) Perceptions of Stimulant Availability; e) 
Perceptions of Stimulant Safety; f) Sharing Stimulants with Other Students; and g) 
Perceived Knowledge about Stimulants. All components demonstrated acceptable 
internal consistency (i.e., > 0.7), except for Sharing Stimulants with Other Students 
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(alpha = 0.563), possibly due to suboptimal loadings for two items contributing to this 
component. Two plausible explanations regarding these discrepant findings can be 
offered. First, the present study used a different method (i.e., Velicer’s MAP and 
Horn’s parallel analysis, principal components analysis [O’Connor, 2000]) to 
determine the number of components than did Weyandt and colleagues (2009; 
principal-axis factor analysis). Second, psychometric non-equivalence of measures 
across cultures is a well-known phenomenon in cross-cultural research (Rottig, 2009). 
Cultural non-equivalence of measures can lead to difficulty with the interpretation of 
findings in different groups (Rottig, 2009); however, even though the current results 
suggested another set of underlying components relative to the original version of the 
SSQ, qualitatively, the Icelandic components appear to represent constructs similar to 
the original four factors, including self-reported stimulant misuse, perceptions of other 
students’ use of stimulants, as well as perceptions of stimulant safety. Therefore, it can 
be concluded that the SSQ is indeed measuring prescription stimulant misuse and 
related beliefs and perceptions among college students in Iceland, similar to the 
original, English language version of the instrument. 
Prescription Stimulant Misuse Findings: Prevalence and Motivations 
The present study was the first to identify prescription stimulant misuse among 
college students in Iceland, which is surprising given the high rate of prescriptions 
issued each year in Iceland. Results revealed that within the overall sample, 
prevalence of lifetime prescription stimulant misuse was 13.2% (95% CI: [10.26%, 
16.14%]), among those without a current prescription for stimulant medication, the 
overall prevalence of lifetime prescription stimulant misuse was 11.2% (95% CI: 
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[8.34%, 14.06%]), while among those holding a prescription it was 42.4% (95% CI: 
[25.79%, 59.01%]). Based on descriptive data, participants holding a prescription for 
stimulant medication generally reported higher levels of stimulant misuse across all 
items of the SSQ. Approximately 8% of participants without a current prescription for 
stimulants reported having used these medications to enhance their academic, 
cognitive, physical, or social performance while about 10% of participants from this 
same group reported having used stimulants to party or to “get high”. These findings 
are within the same range (i.e., 3-20%) as those reported in Germany and Switzerland 
(e.g., Deline et al., 2014; Dietz et al., 2013; Mache et al., 2012); it is important to note, 
however, that prevalence estimates reported in these three studies also encompassed 
other substances (e.g., cannabis, amphetamine, caffeine, etc.), which may complicate 
comparisons with the present results. On the other hand, Maier et al. (2013) 
specifically examined rates of MPH and AMP misuse among university students in 
Switzerland, reporting a prevalence rate of 4.5%. Taken together, these findings 
indicate that prevalence of misuse of prescription stimulants is comparable, or 
possibly higher, among college students in Iceland relative to Germany and 
Switzerland.  
Compared to the United States, Icelandic prevalence rates are also within the 
range of what has been found across studies (i.e., 5.3% - 35%; Weyandt et al., 2013b), 
although prevalence estimates from Benson and colleagues’s (2015) meta-analysis 
approximate around 17%, which is higher than those of the current study. Based on 
these findings, it is plausible that prevalence of stimulant misuse behavior is higher in 
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Iceland than in Europe, but lower than in the United States. More research is needed to 
further examine this hypothesis.  
In terms of motivations for misusing stimulant medication, the most commonly 
endorsed reason, regardless of prescription status, was to enhance academic 
performance (i.e., “to perform better in schoolwork” [53.7% among participants with a 
history of stimulant misuse]). This is in accordance with the literature from both the 
United States (e.g., Benson et al., 2015; Weyandt et al., 2013b), as well as Europe 
(Deline et al., 2014; Dietz et al., 2013; Mache et al., 2012; Maier et al. 2013), 
reporting desired improvement of academic performance as the main reason for 
stimulant misuse. These findings lend support to the notion that students may use 
prescription stimulants as a support strategy and further suggests these students 
perceive themselves as struggling academically. Other commonly endorsed reasons 
included cognitive and physical enhancement (e.g., “to perform better on tests” 
[43.3% among participants with a history of stimulant misuse] or “to feel more 
energetic” [44.8% among participants with a history of stimulant misuse]) as well as 
recreational motivations (e.g., “to get high” [28.4% among participants with a history 
of stimulant misuse]). 
As a group, participants with and without a valid prescription generally felt 
neutral or disagreed that misuse of prescription stimulants is a problem on campus, 
and that stimulants are easily accessible. These results differ from findings reported by 
Weyandt et al. (2009), wherein 50% of participants agreed or strongly agreed that 
stimulants are easily obtainable. These findings are also interesting given that 
approximately 13% of the entire sample reported having engaged in one or more 
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stimulant misuse behaviors at least rarely. Therefore, it appears that although stimulant 
misuse is indeed occurring among college students in Iceland, students may not 
necessarily be aware of it and/or may not perceive this behavior as particularly 
problematic. 
Based on descriptive data, a higher percentage (i.e., 17.6% – 32.4%) of 
Icelandic participants holding a prescription for stimulants agreed or strongly agreed 
that occasional and/or daily stimulant misuse is harmless compared to those without a 
prescription (i.e., 1.9% - 7.4%). Students with a prescription also reported feeling 
more knowledgeable about stimulant medications and their side effects than students 
without a prescription, as would be expected. A large majority of participants with and 
without a prescription reported knowing about peers who engage in stimulant misuse 
behavior for academic, cognitive, or recreational reasons. Finally, more than half of 
the students holding a prescription reported hiding their medication to prevent their 
peers from taking them, similar to results reported by Weyandt et al. (2009). 
Findings indicated a significant, positive association between use of stimulants 
for academic, cognitive, and other enhancement reasons and use of stimulants for 
recreational reasons. Stimulant use for both reasons was also significantly correlated 
with sharing stimulants with peers (i.e., diversion) and increased perceptions of 
stimulant safety, as well as greater perceived knowledge about stimulants.   
Group Differences based on Stimulant Misuse History 
 Group differences in psychological functioning based on stimulant misuse 
history status among students without a current prescription were also of interest. 
Findings suggested past 6-month total number of ADHD symptoms as well as 
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childhood total symptoms of ADHD were significantly higher in the group reporting a 
history of stimulant misuse than among those without such history. In contrast, 
depression, anxiety, and stress were not statistically different across the two groups. 
Overall, the results support the hypothesis that Icelandic college students who misuse 
stimulants are more likely to demonstrate ADHD symptomatology relative to non-
users. Future studies are needed to examine this association in greater detail. 
In addition, participants reporting a history of stimulant misuse scored 
significantly higher than those without such history with regard to perceptions of 
stimulant safety, sharing stimulants with peers, and perceived knowledge about 
stimulants. These results have critical implications for prevention and intervention 
targeting stimulant misuse behavior, and highlight the importance of educating college 
students about the risks associated with misuse of these drugs. Given that many 
students appear to acquire stimulants from peers with a valid prescription (see 
Weyandt et al., 2013b) it behooves physicians who prescribe stimulant medication to 
emphasize the numerous risks associated with stimulant medication diversion and 
misuse with their patients. 
Factors Predictive of Prescription Stimulant Misuse 
The present study identified several variables that are predictive of stimulant 
misuse behavior among college students in Iceland. Preliminary correlational analyses 
revealed Use of Stimulants for Academic, Cognitive, Physical, and Social 
Enhancement was significantly and positively correlated with anxiety and ADHD 
symptoms in childhood. Alternatively, Use of Stimulants for Partying or Getting High 
was positively and significantly correlated with participant sex, wherein being male 
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was associated with greater use, and with childhood and past 6-month symptoms of 
ADHD. No significant correlations between depressive symptoms, stress, or GPA and 
stimulant misuse behavior were observed. 
The first hypothesis, that male sex would be more strongly associated with 
stimulant misuse than female sex, was supported, although the effect size was small. 
Participants who were male were significantly more likely to endorse having engaged 
in prescription stimulant misuse for partying or “getting high”, but not for academic, 
cognitive, or other enhancement reasons. The current results echo findings reported by 
Weyandt and colleages (2013b) as well as Benson et al. (2015) regarding greater 
misuse among males relative to females, although neither of those studies specified the 
primary motives behind this behavior among males, compared to females. 
Contrary to expectations, the second hypothesis, that self-reported GPA would 
be negatively associated with prescription stimulant misuse, was not supported. These 
findings can be contrasted with those reported by Benson et al. (2015) wherein a lower 
GPA was associated with greater odds of engaging in stimulant misuse. It is unclear 
why this relationship did not emerge in the current study, but one possible explanation 
is that grading conventions differ across the two countries and GPA may therefore 
differentially associate with other outcomes.  
The third hypothesis, that symptoms of depression, anxiety, and stress would 
be positively associated with prescription stimulant misuse was partially supported. 
Anxiety, but not depression or stress, was significantly and positively associated with 
use of stimulants for academic, cognitive, and other enhancement reasons (small effect 
size); however no significant associations were found for use of stimulants for 
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recreational reasons. This provides further support to the hypothesis that students who 
struggle academically may use stimulant medications to help cope with educational 
demands.  
The fourth hypothesis, that ADHD symptoms would significantly predict 
prescription stimulant misuse while controlling for symptoms of depression, anxiety, 
and stress was supported; both childhood and past 6-month total symptoms of ADHD 
significantly predicted stimulant use for academic, cognitive, and other enhancement 
reasons, with a small effect size. Interestingly, however, the relationship between 
childhood ADHD symptoms and stimulant misuse was positive while for past 6-
month ADHD symptoms it was negative, indicating greater past 6 month ADHD 
symptomatology is associated with lower use of stimulants for academic, cognitive, 
and other enhancement reasons. In contrast, correlational analyses suggested ADHD 
symptoms in both childhood and adulthood were positively associated with stimulant 
misuse behavior. It is unclear why the relationship between ADHD symptoms and 
stimulant misuse behavior was different for childhood compared to adulthood when 
both constructs were included in the same regression model; one plausible explanation 
is the relatively high correlation (i.e., r = 0.74) between ADHD symptoms in 
adulthood and childhood, possibly suggesting multicollinearity (see Kraha, Turner, 
Nimon, Zientek, & Henson, 2012). With regard to stimulant use for recreational 
reasons, only childhood symptoms of ADHD emerged as a significant, positive 
predictor. Collectively, the findings support the notion that a history of ADHD 
symptoms increases the likelihood of misuse of stimulant medication. Further research 
is needed to examine this relationship in greater detail. 
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The present findings have the potential to inform public health policies 
concerning college student mental health and well-being as well as stimulant 
medication management in Iceland. Greater access to psychological and academic 
support services for students who struggle due to ADHD, ADHD symptomatology, or 
other psychological difficulties may be beneficial and provide students with safer and 
more appropriate strategies for coping with the challenges of the college environment. 
Additionally, psychoeducational interventions regarding the risks of psychostimulant 
medication diversion and misuse are clearly warranted, especially within the college 
population.  
ADHD Symptomatology Findings 
The prevalence of persistent (i.e., occurring both in childhood and adulthood), 
significant ADHD symptomatology within the sample as a whole was 8.0% (95% CI: 
[5.52%, 10.48%]) while 9.1% of participants reported having been previously 
diagnosed with ADHD. The correlation (r = 0.42, p < 0.01), or agreement, between 
significant ADHD symptomatology and having a previous ADHD diagnosis was 
statistically significant. Moreover, 38% of participants meeting study criteria for 
significant ADHD symptoms reported a previous diagnosis of ADHD, compared with 
about 6% of participants without significant ADHD symptoms. Conversely, only 35% 
of participants reporting a previous diagnosis of ADHD were classified as having 
significant ADHD symptoms. 
Therefore, results indicate more than 60% of participants identified as having 
significant ADHD symptoms had not been formally diagnosed with ADHD. This 
suggests the present definition of “significant ADHD symptoms” may have lacked 
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specificity, leading to a number of false positives, and/or many of the participants 
identified truly have ADHD that has not been diagnosed. It is important to note, 
however, that “significant ADHD symptoms”, as defined in the current study, should 
not be conceptualized as a formal ADHD diagnosis given that this categorization is 
solely based on self-reported rating scale data. Instead, these numbers provide a rough 
estimate of the prevalence of problems associated with attention and/or 
hyperactivity/impulsivity that in some cases may warrant clinical attention. 
These results are inconsistent with those reported by Gudjonsson and 
colleagues (2009) who also investigated the prevalence of ADHD among college 
students in Iceland. Gudjonsson et al (2009) found only 1 out of 369 participants met 
somewhat more stringent criteria for the disorder, while the prevalence of 
subthreshold ADHD, or ADHD in partial remission, was 10%, which is more 
comparable to the current findings. Further, in the Gudjonsson et al. (2009) study, the 
percentage of students reporting a prior diagnosis of ADHD was 1%, which is also 
lower than the current results suggested. Although both studies relied on convenience 
samples, a particular strength of the present study was the recruitment of participants 
from the four largest universities in Iceland, whereas Gudjonsson and colleagues 
(2009) recruited participants from one university only. Therefore, it can be argued that 
the current sample was somewhat more representative of the larger Icelandic college 
student population. 
Results suggested as a group, Icelandic college students with elevated ADHD 
symptoms experience greater psychological distress relative to those with fewer 
ADHD symptoms, as these participants reported significantly higher levels of 
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depression, anxiety, and stress, with effect sizes in the medium to large range. In 
contrast, no statistically significant differences in stimulant misuse behavior based on 
ADHD symptomatology status were found.  
Regarding treatment, approximately 20% of participants with significant 
ADHD symptomatology, as defined in the present study, reported holding a current 
prescription for stimulant medication, compared with 4.5% of those not meeting 
criteria for significant ADHD symptomatology. Therefore, a large majority of 
participants with significant ADHD symptoms, as defined in the current study, were 
not prescribed medication to address these symptoms. Conversely, approximately 60% 
of participants reporting a previous ADHD diagnosis endorsed having been prescribed 
stimulant medication. 
The present findings suggest that a significant subgroup of Icelandic college 
students demonstrate elevated ADHD symptomatology. Whether or not these students 
would meet diagnostic criteria for the disorder is unclear; however, the current results 
indicate these students are at greater risk for symptoms of depression, anxiety, and 
stress, relative to those without significant ADHD symptoms. These findings add to a 
growing body of literature that attests to the relationship between ADHD 
symptomatology and a variety of psychosocial difficulties among college students 
(e.g., Anastopoulos et al., in press; Weyandt & DuPaul, 2013). The findings also 
highlight the importance of providing these students with effective treatment and 
support in the college environment. Research regarding treatment of ADHD in college 
students is scarce and preliminary; however, findings reported by Anastopoulos and 
King (2015) concerning a treatment program for college students with ADHD, 
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consisting of cognitive behavior therapy (CBT) and individual mentoring, were 
promising and included greater ADHD knowledge, enhanced organizational skills, and 
increased adaptive thinking. Similarly, LaCount, Hartung, Shelton, Clapp, and Clapp 
(2015) reported a decrease in self-reported ADHD symptoms and academic 
impairment as a result of individual and group CBT sessions targeting organizational 
and time-management skills among college students with elevated ADHD symptoms. 
Finally, Fleming, McMahon, Moran, Peterson, and Dreessen (2015) conducted a 
randomized controlled pilot trial offering group sessions of dialectical behavior 
therapy (DBT) to college students with ADHD. DBT training was associated with 
greater improvement in ADHD symptoms and quality of life than the control 
condition. Increased availability and access to similar support services for college 
students in Iceland, especially those who struggle with ADHD symptoms and other 
psychosocial difficulties, may be warranted.  
Additional Post Hoc Findings 
Group differences based on disability status were also explored. Within the 
group without a current prescription for stimulant medication, results revealed 
participants endorsing having some form of a disability were not significantly more or 
less likely than participants without disabilities to disclose a history of stimulant 
misuse. These findings are similar to those reported by Janusis and Weyandt (2010) 
who found that this same pattern of results emerged when students holding a current 
prescription for stimulant medication were included in the analyses. The current 
findings should be interpreted with caution, however, as results suggested significant 
heterogeneity of variance across groups. 
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In contrast, as a group, students reporting a disability endorsed significantly 
higher levels of depression, anxiety, and stress than students without a disability. 
Hence, it is important that college students with disabilities be offered and encouraged 
to access academic and psychosocial support services. 
Limitations and Future Directions 
Several limitations of the present study should be discussed. First, the current 
study employed a convenience sample, which may limit the generalizability of the 
findings. As noted previously, although the current sample included students from the 
four largest universities in Iceland, the extent to which it represents the larger college 
student population in Iceland is unclear. Second, the sample was disproportionately 
female, which also may serve to reduce the generalizability of the findings. Given the 
current results that males were more likely than females to engage in stimulant misuse 
for recreational reasons, it is possible that the present study underestimated the 
prevalence of this behavior among male college students. Third, assumptions of 
normality and homoscedasticity for t-test and regression analyses may not have been 
met, emphasizing the need for cautious interpretation of the findings. Fourth, the study 
was correlational in design and, as such, does not permit any causal inferences 
regarding the relationship between the variables of interest. Fifth, the current study did 
not address other substance use behavior (e.g., use of alcohol, tobacco, marijuana, 
etc.), which may be an important correlate of stimulant misuse behavior (Benson et al., 
2015). Finally, the age range of participants in the current study was much wider (i.e., 
19-57 years) than that of participants in similar studies conducted in the United States 
(i.e., typically 18-25 years). 
50 
 
Future studies regarding prescription stimulant misuse using representative 
samples of college students in Iceland are needed. Ideally, such studies would be 
longitudinal and prospective in nature, include a rigorous assessment of ADHD and 
related psychosocial issues, and address the potential relationship between prescription 
stimulant misuse and other substance use behaviors. Additionally, although the current 
study was not neurobiologically focused, future research is needed to elucidate the 
pathophysiology of ADHD symptomatology and comorbid conditions (e.g., anxiety 
and depression) and the effects of psychostimulants on these biological mechanisms. 
Conclusion 
The current study was the first to investigate misuse of prescription stimulant 
medication among college students in Iceland. Results revealed a prevalence rate of 
approximately 11% among participants without a prescription for stimulants, 42% 
among participants with a prescription, and 13% within the overall sample (among 
participants with and without a current prescription). Based on these findings, the 
prevalence of this behavior appears to be higher in Iceland than in other European 
countries, but lower than in the United States. Participants reported the primary and 
secondary reasons for misusing stimulants included academic, cognitive, physical, and 
social enhancement as well as partying and/or getting high, similar to results from 
studies conducted with college students in the United States and in Europe. 
Preliminary evidence from the current study indicates risk factors for 
prescription stimulant misuse among college students in Iceland include being male, 
experiencing symptoms of anxiety, and having a history of ADHD symptoms. The 
results of the current study also revealed that approximately 8% of Icelandic college 
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students sampled reported persistent, elevated ADHD symptomatology, and students 
with a history of prescription stimulant misuse had significantly higher ADHD 
symptoms than those without such history.  
Interestingly, correlational analyses suggested a positive relationship between 
ADHD symptoms and stimulant misuse, both with regard to childhood and adulthood 
ADHD symptoms. Multiple regression analyses, however, presented a more 
complicated picture, wherein childhood symptoms of ADHD were positively 
associated with stimulant misuse, and current ADHD symptoms negatively predicted 
stimulant misuse. Cautious interpretation of these results is warranted, however, given 
the study’s limitations. 
The present findings have important implications for public health policy in 
Iceland, particularly as it relates to the college population. Educating college students 
about the risks of ADHD prescription stimulant medication misuse and diversion is 
clearly warranted. Given that many college students who misuse prescription 
stimulants appear to do so to “self-medicate”, or to cope with the various challenges 
they face, it is critically important to provide students with safer strategies to manage 
academic demands in order to promote health and well-being. 
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Table 1. Participant demographics 
Category N Percent 
Sex   
Female 424 81.4 
Male 97 18.6 
Race/Ethnicity   
White 517 99.2 
Non-White 3 0.6 
Other 1 0.2 
ADHD Diagnosis 47 9.0 
Disability 69 13.2 
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Table 2. Initial, 8-component PCA with Varimax rotation 
Item Component 
1 2 3 4 5 6 7 8 
1. I have used prescription stimulants 
for non-medical purposes. .424 .728 
-
.111 .007 .114 .102 .090 
-
.141 
2. I have used prescription stimulants 
at parties. .194 .892 
-
.156 
-
.042 .083 .079 .085 .026 
3. I have used prescription stimulants 
with alcohol. .250 .858 
-
.125 
-
.034 .076 .080 .100 .023 
4. I have snorted prescription 
stimulants. .066 .664 
-
.206 
-
.021 .104 .006 .020 0.55 
5. I have injected prescription 
stimulants. N/A N/A N/A N/A N/A N/A N/A N/A 
6. I have smoked prescription 
stimulants. .072 .338 
-
.099 .045 
-
.032 
-
.109 
-
.015 .550 
7. I have taken prescription stimulants 
to focus better in class. .851 .199 
-
.073 
-
.003 .115 .092 .019 
-
.027 
8. I have taken prescription stimulants 
to perform better on tests. .889 .133 
-
.041 
-
.032 .119 .003 .053 
-
.083 
9. I have taken prescription stimulants 
to help me socialize better. .465 .388 
-
.126 .027 .054 .562 .018 .194 
10. I have taken prescription 
stimulants to help me lose weight. .534 .347 
-
.030 .058 
-
.140 
-
.153 
-
.008 .382 
11. I have taken prescription 
stimulants to perform better in my 
school work. .874 .180 
-
.043 .009 .120 .151 .068 
-
.076 
12. I have taken prescription 
stimulants to feel more energetic. .775 .307 
-
.030 
-
.017 .032 .326 .049 .144 
13. I have taken prescription 
stimulants to feel better about myself. .706 .234 .001 .039 
-
.069 .372 
-
.020 .303 
14. I have taken prescription 
stimulants to “get high”. .109 .791 
-
.093 .130 
-
.035 .053 
-
.028 .224 
15. I have been offered prescription 
stimulants by other students. .198 .396 
-
.305 .198 .014 .061 
-
.091 
-
.156 
16. I have tried someone else’s 
prescription stimulant medication. .373 .546 
-
.097 .107 .020 .256 
-
.045 
-
.021 
17. I have purchased prescription 
stimulants from other students. .155 .186 
-
.109 .108 .069 .762 .057 
-
.102 
18. I have sold prescription stimulant 
medication to other students. .273 
-
.001 
-
.082 .020 .139 .757 .045 
-
.176 
19. I have given prescription 
stimulant medication to other 
students. .535 .315 
-
.053 
-
.051 .114 .076 .081 
-
.406 
20. I have been pressured into letting 
someone else have my prescription 
stimulant medication. .449 .007 
-
.136 .090 .110 
-
.445 .143 
-
.180 
21. Prescription stimulants are easy to 
get on this campus. .033 .100 
-
.144 .846 .089 .052 
-
.011 
-
.113 
22. Prescription stimulants are as easy 
to get as alcohol. 
-
.004 .012 
-
.047 .840 
-
.017 
-
.011 .055 .066 
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23. Prescription stimulants are as easy 
to get as marijuana. .040 .077 
-
.073 .821 .138 .056 .037 .014 
24. Using prescription stimulants 
occasionally is harmless. .152 .232 
-
.056 .006 .730 
-
.021 
-
.023 
-
.224 
25. Using prescription stimulants 
daily is harmless. .128 
-
.054 .076 .044 .746 
-
.060 .014 
-
.056 
26. Prescription stimulant use on 
campus is a problem. 
-
.118 
-
.166 
-
.294 .500 .043 .001 .176 .211 
27. Prescription stimulants are safer 
than marijuana. 
-
.070 .058 .082 .064 .742 .125 
-
.065 .139 
28. Prescription stimulants are safer 
than alcohol.  .114 .068 .038 .105 .814 .101 
-
.018 .026 
29. I feel I am knowledgeable about 
prescription stimulants. .067 .055 
-
.103 .088 
-
.072 .040 .944 
-
.026 
30. I feel I am knowledgeable about 
the side effects of prescription 
stimulants. .114 .081 
-
.110 .075 
-
.031 .006 .941 
-
.016 
31. I know students who use 
prescription stimulants at parties. 
-
.092 
-
.172 .845 
-
.083 .072 
-
.102 
-
.112 .019 
32. I know students who use 
prescription stimulants with alcohol. 
-
.096 
-
.197 .838 
-
.074 .063 
-
.107 
-
.096 .021 
33. I know students who use 
prescription stimulants with other 
drugs. 
-
.024 
-
.273 .737 
-
.085 .010 
-
.048 
-
.075 
-
.113 
34. I know students who use 
prescription stimulants while 
studying. 
-
.216 
-
.185 .682 
-
.240 
-
.010 .016 
-
.078 .302 
35. I know students who use 
prescription stimulants during finals 
week/tests. 
-
.215 
-
.103 .659 
-
.246 .011 .071 
-
.051 .291 
36. I know students who snort 
prescription stimulants. .120 
-
.150 .661 
-
.062 .030 .028 
-
.024 
-
.088 
37. I know students who inject 
prescription stimulants. .009 .167 .442 .198 
-
.009 
-
.027 .004 
-
.187 
38. I know students who smoke 
prescription stimulants. 
-
.011 
-
.021 .577 
-
.073 .025 
-
.017 .083 
-
.405 
39. I hide my prescription stimulant 
medication so that no one will take it. 
-
.343 .100 .138 
-
.058 
-
.188 .259 
-
.229 
-
.287 
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Table 3. Final, 7 component PCA with Varimax rotation 
Item Component 
1 2 3 4 5 6 7 
1. I have used prescription stimulants for non-
medical purposes. .431 .662 
-
.126 
-
.025 .191 .162 .161 
2. I have used prescription stimulants at parties. 
.203 .874 
-
.154 
-
.056 .113 .106 .105 
3. I have used prescription stimulants with alcohol. 
.256 .840 
-
.124 
-
.048 .106 .110 .119 
4. I have snorted prescription stimulants. 
.081 .661 
-
.204 
-
.030 .123 .019 .031 
6. I have smoked prescription stimulants. 
.121 .448 
-
.088 .102 
-
.126 
-
.247 
-
.128 
7. I have taken prescription stimulants to focus 
better in class. .856 .161 
-
.094 
-
.017 .157 .101 .053 
8. I have taken prescription stimulants to perform 
better on tests. .883 .082 
-
.072 
-
.049 .179 .041 .108 
9. I have taken prescription stimulants to help me 
socialize better. .492 .406 
-
.102 .031 .001 .500 
-
.037 
10. I have taken prescription stimulants to help me 
lose weight. .562 .405 
-
.040 .079 
-
.167 
-
.201 
-
.045 
11. I have taken prescription stimulants to perform 
better in my school work. .876 .131 
-
.063 
-
.010 .167 .165 .108 
12. I have taken prescription stimulants to feel 
more energetic. .827 .295 
-
.044 
-
.018 .044 .154 .052 
13. I have taken prescription stimulants to feel 
better about myself. .753 .263 .003 .053 
-
.111 .267 
-
.068 
14. I have taken prescription stimulants to “get 
high”. .136 .816 
-
.083 .115 
-
.033 .073 
-
.026 
15. I have been offered prescription stimulants by 
other students. .114 .369 
-
.287 .144 .051 .320 
-
.029 
16. I have tried someone else’s prescription 
stimulant medication. .343 .511 
-
.089 .073 .046 .373 
-
.006 
17. I have purchased prescription stimulants from 
other students. .115 .157 
-
.062 .062 .040 .809 .040 
18. I have sold prescription stimulant medication to 
other students. .246 
-
.037 
-
.048 .003 .105 .781 .017 
21. Prescription stimulants are easy to get on this 
campus. .008 .080 
-
.148 .822 .120 .147 .018 
22. Prescription stimulants are as easy to get as 
alcohol. .013 .030 
-
.048 .848 
-
.020 
-
.020 .036 
23. Prescription stimulants are as easy to get as 
marijuana. .041 .081 
-
.062 .815 .138 .079 .036 
24. Using prescription stimulants occasionally is 
harmless. .131 .162 
-
.078 
-
.021 .790 .052 .040 
25. Using prescription stimulants daily is harmless. 
.102 
-
.069 .064 .045 .737 
-
.042 .002 
26. Prescription stimulant use on campus is a 
problem. 
-
.088 
-
.112 
-
.275 .536 
-
.006 
-
.112 .105 
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27. Prescription stimulants are safer than 
marijuana. 
-
.062 .079 .104 .083 .687 .074 
-
.112 
28. Prescription stimulants are safer than alcohol. 
.112 .062 .051 .108 .794 .095 
-
.030 
29. I feel I am knowledgeable about prescription 
stimulants. .064 .044 
-
.098 .096 
-
.077 .032 .932 
30. I feel I am knowledgeable about the side effects 
of prescription stimulants.  .108 .075 
-
.101 .088 
-
.048 .007 .927 
31. I know students who use prescription 
stimulants at parties. 
-
.077 
-
.166 .843 
-
.078 .060 
-
.132 
-
.124 
32. I know students who use prescription 
stimulants with alcohol. 
-
.077 
-
.190 .836 
-
.067 .050 
-
.146 
-
.108 
33. I know students who use prescription 
stimulants with other drugs. .002 
-
.299 .726 
-
.090 .030 
-
.084 
-
.050 
34. I know students who use prescription 
stimulants while studying. 
-
.178 
-
.105 .696 
-
.203 
-
.106 
-
.129 
-
.174 
35. I know students who use prescription 
stimulants during finals week/tests. 
-
.189 
-
.025 .680 
-
.210 
-
.092 
-
.058 
-
.154 
36. I know students who snort prescription 
stimulants. .119 
-
.176 .650 
-
.071 .047 .028 
-
.010 
37. I know students who inject prescription 
stimulants. 
-
.002 .122 .434 .158 .053 .061 .069 
38. I know students who smoke prescription 
stimulants. 
-
.045 
-
.111 .563 
-
.129 .114 .116 .183 
Notes. The columns in which item component loadings are bolded represent the 
component to which each item belongs. In cases where more than 1 component 
loading is bolded, the underlined loading represents the component to which the item 
was ultimately added. 
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Table 4. SSQ Components, eigenvalues, and % of variance explained 
SSQ Component Eigenvalues % of 
Variance 
Cumulative 
% 
SSQ Component 1 - 
Use of Stimulants for Academic, Cognitive, 
Physical, or Social Enhancement 4.61 13.56% 13.56% 
SSQ Component 2 - 
Use of Stimulants for Partying or Getting High 4.36 12.81% 26.37% 
SSQ Component 3 - 
Knowledge of Other Students’ Use of Stimulants 4.20 12.36% 38.73% 
SSQ Component 4 - 
Perceptions of Stimulant Availability 2.61 7.67% 46.40% 
SSQ Component 5 - 
Perceptions of Stimulant Safety 2.56 7.54% 53.93% 
SSQ Component 6 - 
Sharing Stimulants with Other Students 1.97 5.79% 59.73% 
SSQ Component 7 - 
Perceived Knowledge about Stimulants 1.93 5.67% 65.40% 
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Table 5. Correlation matrix for the 7 components of the Icelandic translation of the 
SSQ among participants without a current prescription 
SSQ Component C1 C2 C3 C4 C5 C6 C7 
SSQ Component 1 - 
Use of Stimulants for Academic, 
Cognitive, Physical, or Social 
Enhancement 
1 .554
**
 
-
.231
**
 
.032 .188
**
 .463
**
 .155
**
 
SSQ Component 2 - 
Use of Stimulants for Partying or 
Getting High 
.554
**
 1 
-
.359
**
 
.081 .179
**
 .512
**
 .148
**
 
SSQ Component 3 - 
Knowledge of Other Students’ Use of 
Stimulants 
-
.231
**
 
-
.359
**
 
1 
-
.305
**
 
.009 
-
.381
**
 
-
.226
**
 
SSQ Component 4 - 
Perceptions of Stimulant Availability 
.032 .081 
-
.305
**
 
1 .121
**
 .153
**
 .151
**
 
SSQ Component 5 - 
Perceptions of Stimulant Safety 
.188
**
 .179
**
 .009 .121
**
 1 .173
**
 -.038 
SSQ Component 6 - 
Sharing Stimulants with Other Students 
.463
**
 .512
**
 
-
.381
**
 
.153
**
 .173
**
 1 .109
*
 
SSQ Component 7 - 
Perceived Knowledge about Stimulants 
.155
**
 .148
**
 
-
.226
**
 
.151
**
 -.038 .109
*
 1 
Notes. * = Correlation is significant at the 0.05 level. ** = Correlation is significant at 
the 0.01 level 
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Table 6. Prevalence of stimulant misuse behaviors 
Item % endorsing item/behavior as having occurred 
at least “rarely” 
 Total 
N=521 
n=487 without 
prescription 
n=34 with 
prescription 
1. I have used prescription stimulants for 
non-medical purposes. 
9.3% 9.0% 14.7% 
2. I have used prescription stimulants at 
parties. 
6.2% 6.1% 8.8% 
3. I have used prescription stimulants with 
alcohol. 
6.5% 5.9% 14.7% 
4. I have snorted prescription stimulants. 3.5% 3.3% 5.9% 
5. I have injected prescription stimulants. 0.0% 0.0% 0.0% 
6. I have smoked prescription stimulants. 0.8% 0.6% 2.9% 
7. I have taken prescription stimulants to 
focus better in class. 
4.4% 3.2% 23.5% 
8. I have taken prescription stimulants to 
perform better on tests. 
5.6% 4.0% 29.4% 
9. I have taken prescription stimulants to 
help me socialize better. 
3.1% 2.7% 9.1% 
10. I have taken prescription stimulants to 
help me lose weight. 
2.1% 1.7% 8.2% 
11. I have taken prescription stimulants to 
perform better in my school work. 
7.3% 5.7% 32.4% 
12. I have taken prescription stimulants to 
feel more energetic. 
6.0% 4.9% 23.5% 
13. I have taken prescription stimulants to 
feel better about myself. 
2.3% 1.9% 8.8% 
14. I have taken prescription stimulants to 
“get high”. 
4.0% 4.2% 2.9% 
15. I have been offered prescription 
stimulants by other students. 
7.7% 6.7% 17.6% 
16. I have tried someone else’s prescription 
stimulant medication. 
2.3% 2.1% 5.9% 
17. I have purchased prescription stimulants 
from other students. 
1.2% 1.1% 2.9% 
18. I have sold prescription stimulant 
medication to other students. 
0.4% 0.2% 2.9% 
19. I have given prescription stimulant 
medication to other students. 
1.9% 1.2% 11.8% 
20. I have been pressured into letting 
someone else have my prescription 
stimulant medication. 
2.5% 1.3% 20.6% 
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Table 7. Percentage of students who responded “agree” or “strongly agree” to 
statements concerning prescription stimulant use and availability 
Item % endorsing either “agree” or strongly agree” 
 Overall 
N=521 
n=487 without 
prescription 
n=34 with 
prescription 
21. Prescription stimulants are easy to get 
on this campus. 
11.2% 11.0% 11.8% 
22. Prescription stimulants are as easy to 
get as alcohol. 
7.8% 7.2% 11.8% 
23. Prescription stimulants are as easy to 
get as marijuana. 
18.6% 18.7% 20.6% 
24. Using prescription stimulants 
occasionally is harmless. 
7.9% 7.4% 32.4% 
25. Using prescription stimulants daily is 
harmless. 
2.0% 1.9% 17.6% 
26. Prescription stimulant use on campus 
is a problem. 
13.8% 14.5% 8.8% 
27. Prescription stimulants are safer than 
marijuana. 
4.6% 3.9% 14.7% 
28. Prescription stimulants are safer than 
alcohol.  
4.5% 3.4% 14.7% 
29. I feel I am knowledgeable about 
prescription stimulants. 
45.0% 42.7% 76.5% 
30. I feel I am knowledgeable about the 
side effects of prescription stimulants. 
44.0% 41.3% 85.3% 
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Table 8. Percentage of participants who responded “YES” to statements concerning 
prescription stimulant misuse 
Item % agreeing to statement 
 Overall 
N=521 
n=487 without 
prescription 
n=34 with 
prescription 
31. I know about students who use 
prescription stimulants at parties. 
82.1% 82.1% 85.3% 
32. I know about students who use 
prescription stimulants with alcohol. 
83.5% 83.4% 85.3% 
33. I know about students who use 
prescription stimulants with other drugs. 
91.0% 91.4% 88.2% 
34. I know about students who use 
prescription stimulants while studying. 
78.5% 78.9% 76.5% 
35. I know about students who use 
prescription stimulants during finals 
week/tests. 
76.4% 76.7% 76.5% 
36. I know about students who snort 
prescription stimulants. 
93.5% 93.3% 94.1% 
37. I know about students who inject 
prescription stimulants. 
99.2% 99.2% 100.0% 
38. I know about students who smoke 
prescription stimulants. 
96.5% 96.6% 93.9% 
39. I hide my prescription stimulant 
medication so that no one will take it. 
N/A N/A 55.9% 
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Table 9. Descriptive statistics and independent t-test analyses for SSQ, DASS-21, and 
DSM-IV Checklist scores for participants without a current prescription by stimulant 
misuse history status 
Variable Min Max n=309 no 
history of 
stimulant 
misuse 
M (SD) 
n=39 
history of 
stimulant 
misuse 
M (SD) 
t (346) Cohen’s 
d 
SSQ – Component 1 
Use of Stimulants for Academic, 
Cognitive, Physical, or Social 
Enhancement 
0 21 N/A 4.23 
(5.72) 
N/A N/A 
SSQ – Component 2 
Use of Stimulants for Partying or 
Getting High 
0 17 N/A 3.41 
(3.29) 
N/A N/A 
ΨSSQ – Component 3 
Knowledge of Other Students’ 
Use of Stimulants 
0 8 7.23 
(1.61) 
5.61 
(2.22) 
4.41** 0.96 
SSQ – Component 4 
Perceptions of Stimulant 
Availability 
4 20 10.29 
(3.00) 
10.54 
(3.09) 
-0.48 -0.08 
SSQ – Component 5 
Perceptions of Stimulant Safety 
4 20 6.61 
(2.75) 
8.31 
(2.81) 
-3.57** -0.62 
ΨSSQ – Component 6 
Sharing Stimulants with Other 
Students 
0 8 0.06 
(0.28) 
0.82 
(1.64) 
-2.92** -1.26 
 
SSQ – Component 7 
Perceived Knowledge about 
Stimulants 
2 10 5.98 
(2.50) 
7.18 
(2.57) 
-2.76** -0.48 
ΨADHD Total – past 6 months 0 46 9.37 
(7.89) 
12.46 
(9.58) 
-1.93* -0.38 
ΨADHD Total – childhood 0 54 9.41 
(10.06) 
16.18 
(14.27) 
-2.87** -0.64 
 
DASS-Depression 0 21 3.65 
(4.33) 
3.95 
(4.30) 
-0.41 -0.07 
DASS-Anxiety 0 15 2.06 
(3.04) 
2.74 
(3.20) 
-1.27 -0.22 
DASS-Stress 0 20 4.45 
(4.10) 
4.59 
(3.84) 
-0.22 -0.03 
Notes. Ψ = variances were significantly different across groups, results should be interpreted 
with caution. * = significant at the 0.05 level. ** = significant at the 0.01 level. 
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Table 10. SSQ Use of Stimulants for Academic, Cognitive, Physical, and Social 
Enhancement, and Use of Stimulants for Partying or Getting High Pearson 
correlations with DASS subscales (depression, anxiety, and stress), ADHD total 
scores in childhood and adulthood, participant sex, and self-reported GPA 
Notes. * = Correlation is significant at the 0.05 level. ** = Correlation is significant at 
the 0.01 level. 
 
  
Variable A B C D E F G H I 
A: DASS-21 depression 
1 .604
**
 .707
**
 
-
.036 
-.016 .411
**
 .179
**
 .058 -.036 
B: DASS-21 anxiety 
.604
**
 1 .707
**
 
-
.042 
-.054 .405
**
 .220
**
 .195
**
 .064 
C: DASS21 stress 
.707
**
 .707
**
 1 
-
.025 
-
.106
*
 
.436
**
 .202
**
 .087 .028 
D: GPA -.036 -.042 -.025 1 -.020 -.042 -.010 -.010 -.020 
E: Participant Sex 
-.016 -.054 
-
.106
*
 
-
.020 
1 .060 .190
**
 .023 .147
**
 
F: DSM-IV Checklist: 
ADHD total score past 6 
months 
.411
**
 .405
**
 .436
**
 
-
.042 
.060 1 .729
**
 .089 .105
*
 
G: DSM-IV Checklist: 
ADHD total score childhood 
.179
**
 .220
**
 .202
**
 
-
.010 
.190
**
 .729
**
 1 .216
**
 .200
**
 
H: SSQ Use of Stimulants 
for Academic, Cognitive, 
Physical, or Social 
Enhancement 
.058 .195
**
 .087 
-
.010 
.023 .089 .216
**
 1 .657
**
 
I: SSQ Use of Stimulants for 
Partying or Getting High 
-.036 .064 .028 
-
.020 
.147
**
 .105
*
 .200
**
 .657
**
 1 
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Table 11. Regression analyses with Use of Stimulants for Academic, Cognitive, 
Physical, or Social Enhancement component of SSQ as the dependent variable 
Independent variable(s) t p β F df p adj. R2 
Model 1 
Model summary 
    0.94 1, 468 0.33 0.00 
Sex 0.97 0.33 0.05     
Model 2 
Model summary 
    0.07 1, 364 0.78 0.00 
GPA -0.28 0.78 -0.01     
Model 3 
Model summary 
    6.29 3, 417 <0.001 0.04 
Depression -0.81 0.42 -0.06     
Anxiety 3.84 <0.001 0.26     
Stress -0.54 0.59 -0.04     
Model 4 
Model summary 
    8.08 5, 378 <0.001 0.09 
ADHD past 6 months -2.91 0.004 -0.24     
ADHD childhood 4.65 <0.001 0.34     
Depression -0.51 0.61 -0.04     
Anxiety 3.69 <0.001 0.26     
Stress -0.51 0.61 -0.04     
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Table 12. Regression analyses with Use of Stimulants for Partying or Getting High 
component of SSQ as the dependent variable 
Independent variable(s) t p β F df p adj. R2 
Model 1 
Model summary 
    4.71 1, 468 0.03 0.01 
Sex 2.17 0.03 0.10     
Model 2 
Model summary 
    0.32 1, 457 0.57 0.00 
GPA -0.56 0.57 -0.03     
Model 3 
Model summary 
    1.78 3, 419 0.15 0.01 
Depression -1.56 0.12 -0.112     
Anxiety 1.61 0.11 0.110     
Stress 0.70 0.49 0.056     
Model 4 
Model summary 
    3.81 5,379 0.002 0.04 
ADHD past 6 months -0.96 0.34 -0.08     
ADHD childhood 3.21 0.001 0.24     
Depression -1.77 0.08 -0.13     
Anxiety 1.16 0.25 0.09     
Stress 0.46 0.65 0.04     
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Figure 1. Regression model with Sex as the IV and Use of Stimulants for Academic, 
Cognitive, Physical, or Social Enhancement as the DV: Assessment of independence 
of errors assumption 
Figure 2. Regression model with Sex as the IV and Use of Stimulants for Academic, 
Cognitive, Physical, or Social Enhancement as the DV: Assessment of independence of 
errors assumption 
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Figure 3. Regression model with Sex as the IV and Use of Stimulants for Academic, 
Cognitive, Physical, or Social Enhancement as the DV: Assessment of normal 
distribution assumption 
Figure 4.  Regression model with Sex as the IV and Use of Stimulants for Partying or 
Getting High as the DV: Assessment of independence of errors assumption 
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Figure 5. Regression model with Sex as the IV and Use of Stimulants for Partying 
or Getting High as the DV: Assessment of homogeneity of variance and linearity 
assumption 
 
Figure 6. Regression model with Sex as the IV and Use of Stimulants for 
Partying or Getting High as the DV: Assessment of normal distribution 
assumption 
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Figure 7. Regression model with GPA as the IV and Use of Stimulants for 
Academic, Cognitive, Physical, or Social Enhancement as the DV: Assessment of 
independence of errors assumption 
 
Figure 8. Regression model with GPA as the IV and Use of Stimulants for 
Academic, Cognitive, Physical, or Social Enhancement as the DV: Assessment of 
homogeneity of variance and linearity assumption 
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Figure 9. Regression model with GPA as the IV and Use of Stimulants for Academic, 
Cognitive, Physical, or Social Enhancement as the DV: Assessment of normal distribution 
assumption 
Figure 10. Regression model with GPA as the IV and Use of Stimulants for Partying 
or Getting High as the DV: Assessment of independence of errors assumption 
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Figure 11. Regression model with GPA as the IV and Use of Stimulants for Partying 
or Getting High as the DV: Assessment of homogeneity of variance and linearity 
assumption 
Figure 12. Regression model with GPA as the IV and Use of Stimulants for Partying 
or Getting High as the DV: Assessment of normal distribution assumption 
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Figure 13. Regression model with DASS subscales as the IV and Use of Stimulants for 
Academic, Cognitive, Physical, or Social Enhancement as the DV: Assessment of 
independence of errors assumption 
Figure 14. Regression model with DASS subscales as the IV and Use of Stimulants 
for Academic, Cognitive, Physical, or Social Enhancement as the DV: Assessment of 
homogeneity of variance and linearity assumption 
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Figure 15. Regression model with DASS subscales as the IV and Use of Stimulants 
for Academic, Cognitive, Physical, or Social Enhancement as the DV: Assessment of 
normality assumption 
Figure 16. Regression model with DASS subscales as the IV and Use of Stimulants 
for Partying or Getting High as the DV: Assessment of independence of errors 
assumption 
90 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 17. Regression model with DASS subscales as the IV and Use of 
Stimulants for Partying or Getting High as the DV: Assessment of homogeneity of 
variance and linearity assumption 
Figure 18. Regression model with DASS subscales as the IV and Use of 
Stimulants for Partying or Getting High as the DV: Assessment of normality 
assumption 
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Figure 19. Regression model with DASS subscales and ADHD symptoms as the IV 
and Use of Stimulants for Academic, Cognitive, Physical, and Social Enhancement as 
the DV: Assessment of independence of errors assumption 
Figure 20. Regression model with DASS subscales and ADHD symptoms as the IV 
and Use of Stimulants for Academic, Cognitive, Physical, and Social 
Enhancement as the DV: Assessment of homogeneity of variance and linearity 
assumption 
92 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 21. Regression model with DASS subscales and ADHD symptoms as 
the IV and Use of Stimulants for Academic, Cognitive, Physical, and Social 
Enhancement as the DV: Assessment of normality assumption 
Figure 22. Regression model with DASS subscales and ADHD symptoms as the IVs 
and Use of Stimulants for Partying or Getting High as the DV: Assessment of 
independence of errors assumption 
93 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 23. Regression model with DASS subscales and ADHD symptoms as the 
IVs and Use of Stimulants for Partying or Getting High as the DV: Assessment 
of homogeneity of variance and linearity assumption 
Figure 24. Regression model with DASS subscales and ADHD symptoms as the 
IV and Use of Stimulants for Partying or Getting High as the DV: Assessment of 
normality assumption 
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Figure 25. Distribution of scores on the Use of Prescription Stimulants for Academic, 
Cognitive, Physical, or Social Enhancement component of the SSQ 
Figure 26. Distribution of scores on the Use of Prescription Stimulants for Partying 
or Getting High component of the SSQ 
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Appendix A 
Informed Consent (English) 
The University of Rhode Island 
Department of Psychology 
 
Prevalence of ADHD and Prescription Stimulant Misuse among College Students in 
Iceland 
 
PLEASE PRINT AND KEEP THIS FORM FOR YOURSELF 
 
Dear Participant: 
 
You have been invited to take part in a research project described below. If you have 
any questions, please feel free to contact the student investigator, B. Gyda 
Gudmundsdottir, at +1 (XXX) XXX-XXXX or XXX@my.uri.edu, or the principal 
investigator, Dr. Lisa Weyandt, at +1 (XXX) XXX-XXXX or XXX@uri.edu.   
 
The purpose of this study is to examine the misuse of prescription stimulant 
medications among college students and how it relates to aspects of psychosocial 
functioning, including symptoms of ADHD, depression, anxiety, and stress. 
Responses to survey items are completely anonymous: there will be no identifying 
information linking you to your responses. Data will be encrypted and stored through 
the website SurveyMonkey, and only the primary student investigator will have access 
to the data through the use of a password. 
 
YOU MUST BE AT LEAST 18 YEARS OLD to participate in this research project.  
If you are not, please discontinue the survey at this time.   
 
If you decide to participate in this study, it will involve completing some 
questionnaires pertaining to your perceptions about prescription stimulant medication, 
symptoms of ADHD, depression, anxiety, and stress, and your demographic 
background.   
 
The possible risks of the study are minimal, although you may feel some 
embarrassment answering questions of a personal nature. Please respond honestly, and 
remember that your responses are anonymous. 
 
Although there are no direct benefits of the study, your answers will help to increase 
knowledge and understanding regarding the non-medical use of prescription 
stimulants among college students. 
 
Your participation in this study is anonymous. This means that your answers to all 
questions are private. No one else can know that you participated in this study, and no 
one can find out what your answers were to any items.  Scientific reports will be based 
on aggregated group data, and will not identify you or any individual in this project. 
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The decision to participate in this research project is up to you.  You do not have to 
participate, and you can decline to answer the questionnaires. If you decide to take 
part in the study, you may quit at any time. Whatever you decide will in no way 
penalize you or your status as a student.   Participation in this study is not expected to 
be harmful or injurious to you. 
 
If you have any additional questions or concerns about this study, you may contact the 
student investigator, B. Gyda Gudmundsdottir, at +1 (XXX) XXX-XXXX, her faculty 
sponsor, Dr. Lisa Weyandt, at +1 (XXX) XXX-XXXX, or the University of Rhode 
Island’s Vice President for Research, 70 Lower College Road, Suite 2, URI, Kingston, 
RI; +1 (XXX) XXX-XXXX. 
 
By clicking this box, you are indicating that: 
 You are at least 18 years old.   
 You have read the consent form and your questions have been answered to 
your satisfaction. 
 
  
97 
 
Appendix A (continued) 
 
Informed Consent (Icelandic) 
UPPLÝST SAMÞYKKI 
University of Rhode Island 
Department of Psychology/Sálfræðideild 
 
Algengi ADHD og misnotkunar örvandi lyfseðilsskyldra lyfja meðal háskólanema á 
Íslandi [Prevalence of ADHD and Prescription Stimulant Misuse among College 
Students in Iceland] 
 
VINSAMLEGA GEYMIÐ EINTAK AF ÞESSU EYÐUBLAÐI TIL EIGIN 
AFNOTA. 
 
Kæri þátttakandi: 
 
Þér hefur verið boðið að taka þátt í rannsókn sem lýst er hér að neðan. Vinsamlega 
hafðu samband við rannsakendur, Bergljótu Gyðu Guðmundsdóttur, doktorsnema í 
sálfræði, í síma +1 (XXX) XXX-XXXX eða gegnum tölvupóst: XXX@my.uri.edu, 
eða leiðbeinanda hennar og ábyrgðarmann rannsóknarinnar, Dr. Lisu Weyandt, í síma 
+1 (XXX) XXX-XXXX eða gegnum tölvupóst: XXX@uri.edu. 
 
Markmið þessarar rannsóknar er að kanna misnotkun örvandi lyfseðilsskyldra lyfja 
meðal háskólanema og hvernig slík hegðun tengist ýmsum sálfélagslegum breytum, til 
dæmis einkennum athyglisbrests með ofvirkni (AMO; ADHD), þunglyndis, kvíða og 
streitu. Svör við spurningum eru órekjanleg til einstakra þátttakenda og engum 
persónuupplýsingum verður safnað. Gögn verða dulkóðuð og geymd á vefsíðu 
SurveyMonkey og munu einungis rannsakendur hafa aðgang að gögnunum gegnum 
notendanafn og lykilorð. 
 
ÞÚ VERÐUR AÐ HAFA NÁÐ 18 ÁRA ALDRI til þess að taka þátt í rannsókninni. 
Ef þú ert ekki orðin/-nn 18 ára, vinsamlega hættu þátttöku núna. 
 
Ef þú ákveður að taka þátt í þessari rannsókn muntu verða beðin/-nn um að svara 
spurningum um viðhorf þín til örvandi lyfseðilsskyldra lyfja, notkun slíkra lyfja, og 
einkenna ADHD, þunglyndis, kvíða og streitu, sem og spurningum um bakgrunn þinn. 
 
Áhætta af þátttöku í þessari rannsókn er nánast engin en þér gæti hugsanlega þótt 
óþægilegt að svara spurningum er varða persónulega hagi þína. Vinsamlega svaraðu af 
hreinskilni og mundu að svör þín eru nafnlaus og órekjanleg til þín.  
 
Þótt enginn beinn ávinningur fáist af þátttöku í þessari rannsókn munu svör þín leiða 
til aukinnar þekkingar og skilnings á misnotkun örvandi lyfseðilsskyldra lyfja meðal 
háskólanema. 
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Þátttaka þín í þessari rannsókn er nafnlaus. Það felur í sér að svör þín við öllum 
spurningum eru leynileg. Enginn mun vita að þú hafir tekið þátt í þessari rannsókn og 
enginn mun geta komist að því hverju þú svaraðir. Skýrslur og greinar um þessa 
rannsókn munu byggjast á svörum þátttakenda í heild og ómögulegt verður að rekja 
niðurstöður til einstakra þátttakenda.  
 
Ákvörðun um þátttöku í þessari rannsókn er alfarið þín. Þér ber ekki skylda til að taka 
þátt og þú mátt sleppa því að svara einstökum spurningum og/eða spurningalistum í 
heild. Ef þú ákveður að taka þátt í rannsókninni máttu hætta þátttöku hvenær sem er. 
Hver sem ákvörðun þín verður mun hún ekki hafa áhrif á stöðu þína sem háskólanemi 
á nokkurn hátt. Þátttaka í þessari rannsókn telst áhættulaus. 
 
Ef þú hefur einhverjar spurningar eða athugasemdir vegna rannsóknarinnar hafðu 
vinsamlega samband við rannsakendur, Bergljótu Gyðu Guðmundsdóttur, 
doktorsnema í sálfræði, í síma +1 (XXX) XXX-XXXX, eða leiðbeinanda hennar og 
ábyrgðarmann rannsóknarinnar, Dr. Lisu Weyandt, í síma +1 (XXX) XXX-XXXX, 
eða eftirlitsskrifstofu rannsókna við University of Rhode Island (University of Rhode 
Island’s Vice President for Research), 70 Lower College Road, Suite 2, URI, 
Kingston, Rhode Island, í síma +1 (XXX) XXX-XXXX. 
 
Með því að merkja við hér að neðan staðfestir þú að: 
 
 Þú hefur náð 18 ára aldri. 
 Þú hefur lesið þetta eyðublað um upplýst samþykki og spurningum þínum 
hefur verið svarað á fullnægjandi hátt. 
 
  
99 
 
Appendix B 
Debriefing (English) 
The study that you just participated in examined misuse of prescription 
stimulant medications among college students in Iceland, and the relationship between 
ADHD symptoms, sex, GPA, depressive symptoms, anxiety, and stress among college 
students.   This study, titled, “Prevalence of ADHD and Prescription Stimulant Misuse 
among College Students in Iceland” is being conducted in order to fulfill requirements 
for a doctorate of philosophy degree in psychology.   
The prevalence of misuse of stimulant medications among college students in 
the United States has been well documented in research. This study is the first to 
assess prevalence rates among Icelandic college students and to further examine risk 
factors associated with stimulant misuse in this population.  Results of this 
investigation may help to identify sub-populations of Icelandic college students who 
are at risk for misuse of stimulant medication, and to inform prevention and 
intervention strategies designed to address prescription stimulant misuse. 
 If you have any questions or concerns about this study, please contact Bergljot 
Gyda Gudmundsdottir at +1 XXX-XXX-XXXX or at xxx@gmail.com.  Thank you 
for your time and participation.  
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Appendix B (continued) 
Debriefing (Icelandic) 
Rannsóknin sem þú varst að ljúka þátttöku í felst í því að kanna algengi 
misnotkunar örvandi lyfseðilsskyldra lyfja meðal íslenskra háskólanema og samband 
einkenna athyglisbrests með ofvirkni (AMO eða ADHD), kyns, meðaleinkunnar, 
þunglyndiseinkenna, kvíða og streitu við misnotkun örvandi lyfseðilsskyldra lyfja 
meðal íslenskra háskólanema. Þessi rannsókn, sem ber titilinn “Algengi ADHD 
einkenna og misnotkunar örvandi lyfseðilsskyldra lyfja meðal háskólanema á Íslandi” 
(“Prevalence of ADHD and prescription stimulant misuse among college students in 
Iceland”), er hluti af doktorsverkefni Bergljótar Gyða Guðmundsdóttur í sálfræði við 
University of Rhode Island í Bandaríkjunum. 
Rannsóknir hafa ítrekað sýnt fram á að misnotkun örvandi lyfja eigi sér stað 
meðal háskólanema í Bandaríkjunum. Þetta er fyrsta rannsóknin sem kannar algengi 
misnotkunar örvandi lyfseðilsskyldra lyfja og þætti sem spá fyrir um slíka hegðun 
meðal íslenskra háskólanema. Niðurstöður þessarar rannsóknar geta hjálpað til við að 
skilgreina hvaða undirhópar íslenskra háskólanema eru líklegri til að misnota örvandi 
lyfseðilsskyld lyf en aðrir og geta einnig veitt mikilvægar upplýsingar fyrir forvarnir 
og inngrip á þessu sviði. 
 Ef einhverjar spurningar vakna eða ef þú sérð eitthvað athugavert við þessa 
rannsókn, vinsamlega hafðu samband við Bergljótu Gyðu Guðmundsdóttur í síma +1 
XXX-XXX-XXXX eða gegnum tölvupóst: xxx@gmail.com.  Kærar þakkir fyrir að 
gefa þér tíma til að taka þátt. 
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Appendix C 
Statement on Diversity in Research 
 This research project aimed to recruit participants of both sexes/genders and 
those with and without disabilities, to increase the likelihood that findings would 
equally apply to all individuals within the target population, i.e., college students in 
Iceland, in accordance with the requirements of the Office of Research Compliance 
and the Institutional Review Board. Given the racial/ethnic homogeneity of the 
Icelandic population (Statistics Iceland, 2013), it was considered likely that a large 
majority of participants would identify as White/Caucasian. In addition, because 
approximately 4% of university students are registered as having a disability 
(University of Iceland, 2013), the majority of participants were likely to identify as not 
having a disability. No college student enrolled at any of the target universities was 
excluded from participation; however, to be eligible for participation, participants 
needed to be able to read and write in Icelandic. 
References 
Statistics Iceland. (2013). Population by origin and citizenship. Retrieved from: 
http://statice.is/Statistics/Population/Citizenship-and-country-of-birth.  
University of Iceland. (2013). [Total number of students enrolled at the University of 
Iceland since the beginning]. Heildarskráning nemenda í Háskóla Íslands frá 
upphafi. Retrieved from: 
http://www.hi.is/adalvefur/heildarskraning_nemenda_i_haskola_islands_fra_u
pphafi_0 
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Appendix D 
Demographic Questionnaire (English) 
 
1. Current age (in years): ___________ 
 
2. Sex: 
 
Male 
Female 
Other: __________ 
 
3. Race/Ethnicity (please circle one): 
 
White 
Non-White 
Other: _________ 
 
4. Degree Program in which you are enrolled (please choose one):    
 
Not attending college/university 
Bachelor’s Level 
Master’s Level 
Specialist Level 
Doctoral Level 
Other (please specify): ___________ 
 
5. What is your current GPA (on a scale of 0-10)? _______ 
 
6. Have you ever used prescription stimulant medication (e.g., Ritalin, Ritalin-
Uno, Concerta, Adderall, Vyvanse, etc.) that was not prescribed to you? 
 
Yes  No 
 
7. Have you ever been diagnosed with Attention-Deficit-Hyperactivity Disorder 
(ADHD or ADD)? 
    
Yes  No 
 
8. If you answered “yes” to the previous question, with what 
subtype/presentation of ADHD are you diagnosed? 
 
Hyperactive/Impulsive Type 
Inattentive Type  
Combined Type 
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Do not know 
 
9. If you answered “yes” to the previous question, at what age were you first 
diagnosed? _______ 
 
10. Are you currently taking stimulant medication that has been prescribed to 
you by a doctor, including methylphenidate (e.g. Ritalin, Concerta, Metadate) or 
amphetamine (Adderall, Dexedrine, Desoxyn, Vyvanse)?  
 
Yes  No 
 
11. If “yes” to question 10, have you ever used stimulant medication that was 
prescribed to you in a way other than the manner it was prescribed (e.g. higher 
or more frequent dosage, different method of ingestion)? 
 
Yes  No 
 
12. Do you currently have a disability? 
 
Yes  No 
 
13. If “yes” to the previous question 12, are you currently registered with the 
Disabilities Support Services office at your university? 
Yes                  No 
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Appendix D (continued) 
Demographic Questionnaire (Icelandic) 
 
Bakgrunnsspurningar 
 
1. Aldur (í árum): __________ 
 
2. Kyn: 
 
Karl 
Kona 
Annað: __________ 
 
3. Kynþáttur/uppruni (vinsamlega veldu eitt): 
 
Hvítur (White) 
Ekki hvítur (Non-White) 
Annað (vinsamlega útskýrið): __________ 
 
4. Tegund náms sem þú ert skráð/-ur í (vinsamlega veldu eina): 
   
Ekki skráð/-ur í háskóla  
Grunnnám til bachelor gráðu 
Framhaldsnám til meistara- eða annarrar sérfræðigráðu 
Framhaldsnám til doktorsgráðu 
Annað (vinsamlega útskýrið): ___________ 
 
5. Hver er núverandi meðaleinkunn þín (á kvarðanum 0-10)? _______ 
 
6. Hefur þú einhvern tíma notað örvandi lyfseðilsskyld lyf (t.d. Ritalin, Ritalin-
Uno, Concerta, Adderall o.fl.) sem var ekki ávísað til þín?  
 
Já  Nei 
 
7. Hefur þú einhvern tíma verið greind/-ur með athyglisbrest með (eða án) 
ofvirkni (AMO; attention deficit/hyperactivity disorder; ADHD, ADD)? 
    
Já  Nei 
 
8. Ef þú svaraðir síðustu spurningu játandi, hvaða undirtegund AMO/ADHD 
varst þú greind/-ur með? 
 Athyglisbrestur (Inattentive) 
Hreyfiofvirkni og hvatvísi (Hyperactive/Impulsive)  
Blönduð (Combined) 
Veit ekki 
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9. Ef þú svaraðir síðustu spurningu játandi, hvenær varstu greind/-ur (aldur í 
árum)? _______ 
 
10. Tekur þú örvandi lyf sem hefur verið ávísað til þín af lækni, til dæmis 
metýlfenídat (t.d. Ritalin, Ritalin-Uno, Concerta, o.fl.) eða amfetamínskyld lyf 
(t.d. Adderall, Dexedrine, Desoxyn, Vyvanse)?  
 
Já  Nei 
 
11. Ef þú svaraðir síðustu spurningu játandi, hefur þú einhvern tíma notað 
örvandi lyf sem var ávísað til þín á annan hátt en tilgreint var á lyfseðli (t.d. í 
stærri eða fleiri skömmtum eða með öðrum leiðum en gegnum munn)? 
 
Já  Nei 
 
12. Býrð þú við fötlun af einhverju tagi? 
 
Já  Nei 
 
13. Ef þú svaraðir síðustu spurningu játandi, nýtur þú formlegrar 
þjónustu/aðstoðar vegna fötlunar þinnar í háskólanum sem þú ert skráð/-ur í? 
 
Já                  Nei 
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Appendix E 
DSM-IV Checklist of Symptoms – Past 6 Months (English) 
 
Indicate the number that best describes your behavior over the past 6 months.  
 
0 = Never or rarely 1 = Sometimes 2 = Often 3 = Very Often  
 
1. Fail to give close attention to details or make careless mistakes in my work. ____ 
2. Fidget with my hands or feet or squirm in my seat. ____ 
3. Have difficulty sustaining my attention in tasks or fun activities. ____ 
4. Leave my seat in situations in which remaining seated is expected. ____ 
5. Don’t listen when spoken to directly. ____ 
6. Feel restless ___ 
7. Don’t follow through on instructions and fail to finish work. ____ 
8. Have difficulty engaging in leisure activities or doing fun things quietly. ____ 
9. Have difficulty organizing tasks and activities. ____ 
10. Feel “on the go” or “driven by a motor.” ___ 
11. Avoid, dislike, or feel reluctant to engage in work that requires sustained mental 
effort. ____ 
12. Talk excessively. ____ 
13. Lose things necessary for tasks and activities. ____ 
14. Blurt out answers before questions have been completed. ____ 
15. Easily distracted. ____ 
16. Have difficulty awaiting my turn. _____ 
17. Forgetful in daily activities. ____ 
18. Interrupt or intrude on others. _____ 
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Appendix E (continued) 
DSM-IV Checklist of Symptoms – Childhood (English) 
 
Indicate the number that best describes your behavior when you were a child, prior to 
12 years of age. 
 
0 = Never or rarely 1 = Sometimes 2 = Often 3 = Very Often  
 
1. Fail to give close attention to details or make careless mistakes in my work. ____ 
2. Fidget with my hands or feet or squirm in my seat. ____ 
3. Have difficulty sustaining my attention in tasks or fun activities. ____ 
4. Leave my seat in situations in which remaining seated is expected. ____ 
5. Don’t listen when spoken to directly. ____ 
6. Feel restless ___ 
7. Don’t follow through on instructions and fail to finish work. ____ 
8. Have difficulty engaging in leisure activities or doing fun things quietly. ____ 
9. Have difficulty organizing tasks and activities. ____ 
10. Feel “on the go” or “driven by a motor.” ___ 
11. Avoid, dislike, or feel reluctant to engage in work that requires sustained mental 
effort. ____ 
12. Talk excessively. ____ 
13. Lose things necessary for tasks and activities. ____ 
14. Blurt out answers before questions have been completed. ____ 
15. Easily distracted. ____ 
16. Have difficulty awaiting my turn. _____ 
17. Forgetful in daily activities. ____ 
18. Interrupt or intrude on others. _____ 
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Appendix E (continued) 
DSM-IV Checklist of Symptoms – Past 6 Months (Icelandic) 
Hegðunarmatskvarði fyrir fullorðna 
 
Veldu það svar sem lýsir best hegðun þinni eins og hún var síðustu 6 mánuði. 
 
Aldrei eða sjaldan = 0  Stundum = 1   Oft = 2  Mjög oft = 3 
 
1. Huga illa að smáatriðum eða geri fljótfærnislegar villur í starfi eða námi. ____ 
2. Er mikið með hendur og fætur á hreyfingu eða á iði þegar ég sit. ____ 
3. Á erfitt með að halda athygli vakandi við verkefni eða tómstundaiðju. ____ 
4. Fer úr sæti mínu í aðstæðum þar sem ætlast er til að ég sitji kyrr. ____ 
5. Virðist ekki hlusta þegar talað er beint til mín. ____ 
6. Hreyfi mig óhóflega mikið í aðstæðum þar sem það á ekki við; ofvirk(ur); finnst ég 
vera eirðarlaus.__ 
7. Fylgi ekki fyrirmælum til enda og tekst ekki að ljúka verkefnum. ____ 
8. Á erfitt með að vera hljóð(ur) þegar ég sinni tómstundaiðju. ____ 
9. Á erfitt með að skipuleggja verkefni og athafnir. ____ 
10. Er alltaf á ferðinni, eða „er eins og þeytispjald“. 
11. Forðast verkefni (t.d. í vinnu eða heima) sem krefjast mikillar beitingar hugans. 
____ 
12. Tala óhóflega mikið. ____ 
13. Týni hlutum sem eru nauðsynlegir til verkefna eða athafna. ____ 
14. Gríp fram í með svari áður en spurningum er lokið. ____ 
15. Er auðtrufluð(-aður). ____ 
16. Á erfitt með að bíða eftir að röðin komi að mér. _____ 
17. Er gleymin(n). ____ 
18. Gríp fram í eða ryðst inn í samræður eða athafnir annarra. _____ 
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Appendix E (continued) 
DSM-IV Checklist of Symptoms – Childhood (Icelandic) 
Hegðunarmatskvarði fyrir fullorðna 
 
Veldur það svar sem lýsir best hegðun þinni eins og hún var fyrir 12 ára aldur.  
 
Aldrei eða sjaldan = 0  Stundum = 1   Oft = 2  Mjög oft = 3 
 
1. Huga illa að smáatriðum eða geri fljótfærnislegar villur í starfi eða námi. ____ 
2. Er mikið með hendur og fætur á hreyfingu eða á iði þegar ég sit. ____ 
3. Á erfitt með að halda athygli vakandi við verkefni eða tómstundaiðju. ____ 
4. Fer úr sæti mínu í aðstæðum þar sem ætlast er til að ég sitji kyrr. ____ 
5. Virðist ekki hlusta þegar talað er beint til mín. ____ 
6. Hreyfi mig óhóflega mikið í aðstæðum þar sem það á ekki við; ofvirk(ur); finnst ég 
vera eirðarlaus.__ 
7. Fylgi ekki fyrirmælum til enda og tekst ekki að ljúka verkefnum. ____ 
8. Á erfitt með að vera hljóð(ur) þegar ég sinni tómstundaiðju. ____ 
9. Á erfitt með að skipuleggja verkefni og athafnir. ____ 
10. Er alltaf á ferðinni, eða „er eins og þeytispjald“. 
11. Forðast verkefni (t.d. í vinnu eða heima) sem krefjast mikillar beitingar hugans. 
____ 
12. Tala óhóflega mikið. ____ 
13. Týni hlutum sem eru nauðsynlegir til verkefna eða athafna. ____ 
14. Gríp fram í með svari áður en spurningum er lokið. ____ 
15. Er auðtrufluð(-aður). ____ 
16. Á erfitt með að bíða eftir að röðin komi að mér. _____ 
17. Er gleymin(n). ____ 
18. Gríp fram í eða ryðst inn í samræður eða athafnir annarra. _____ 
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Appendix F 
Depression Anxiety Stress Scale -21 (DASS-21) 
Lestu hverju fullyrðingu og veldu svar 0, 1, 2 eða 3 sem segir til um hve vel hver 
fullyrðing átti við í þínu tilviki síðustu vikuna. Það eru engin rétt eða röng svör. 
Eyddu ekki of miklum tíma í að velta fyrir þér hverri fullyrðingu. 
 
[Please read each statement and circle a number 0, 1, 2, or 3 that indicates how much 
that statement applied to you over the past week. There are no right or wrong 
answers. Do not spend too much time on any statement]. 
 
0 = Átti alls ekki við mig. [Did not apply to me at all]. 
1 = Átti við mig að einhverju leyti eða stundum. [Applied to me to some degree, or 
some of the time]. 
2 = Átti töluvert vel við mig eða drjúgan hluta vikunnar. [Applied to me to a 
considerable degree, or a good part of time]. 
3 = Átti mjög vel við mig eða mest allan tímann. [Applied to me very much, or most of 
the time]. 
 
1. Mér fannst erfitt að ná mér niður. [I found it hard to wind down]. ____ 
2. Ég fann fyrir munnþurrki. [I was aware of dryness of my mouth]. ____ 
3. Ég virtist alls ekki geta fundið fyrir neinum góðum tilfinningum. [I couldn’t seem to 
experience any positive feeling at all]. ____ 
4. Ég átti í erfiðleikum með að anda (t.d. allt of hröð öndun, mæði án líkamlegrar 
áreynslu). [I experienced breathing difficulty (e.g. excessively rapid breathing, 
breathlessness in the absence of physical exertion)]. ____ 
5. Mér fannst erfitt að hleypa í mig krafti til að gera hluti. [I found it difficult to work 
up the initiative to do things]. ____ 
6. Ég hafði tilhneigingu til að bregðast of harkalega við aðstæðum. [I tended to over-
react to situations].____ 
7. Ég fann fyrir skjálfta (t.d. í höndum). [I experienced trembling (e.g. in the 
hands)].____ 
8. Mér fannst ég eyða mikilli andlegri orku. [I felt that I was using a lot of nervous 
energy]. ____ 
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9. Ég hafði áhyggjur af aðstæðum þar sem ég fengi hræðslukast (panic) og gerði mig 
að fífli. [I was worried about situations in which I might panic and make a fool of 
myself].___ 
10. Mér fannst ég ekki geta hlakkað til neins. [I felt that I had nothing to look forward 
to]. ____ 
11. Ég var ergileg(ur). [I found myself getting agitated]. ____ 
12. Mér fannst erfitt að slappa af. [I found it difficult to relax]. ____ 
13. Ég var dapur/döpur og niðurdregin(n). [I felt down-hearted and blue]. ____ 
14. Ég þoldi ekki þegar eitthvað kom í veg fyrir að ég héldi áfram við það sem ég var 
að gera. [I was intolerant of anything that kept me from getting on with what I was 
doing]. ____ 
15. Mér fannst ég nánast gripin(n) skelfingu. [I felt I was close to panic]. ____ 
16. Ég gat ekki fengið brennandi áhuga á neinu. [I was unable to become enthusiastic 
about anything]. ____ 
17. Mér fannst ég ekki vera mikils virði sem manneskja. [I felt I wasn’t worth much as 
a person]. ____ 
18. Mér fannst ég frekar hörundsár. [I felt that I was rather touchy]. ____ 
19. Ég varð vör(var) við hjartsláttinn í mér þó ég hefði ekki reynt á mig (t.d. hraðari 
hjartsláttur, hjartað sleppti úr slagi). [I was aware of the action of my heart in the 
absence of physical 
exertion (e.g. sense of heart rate increase, heart missing a beat)]. ____ 
20. Ég fann fyrir ótta án nokkurrar skynsamlegrar ástæðu. [I felt scared without any 
good reason].____ 
21. Mér fannst lífið vera tilgangslaust. [I felt that life was meaningless]. ____ 
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Appendix G 
Stimulant Survey Questionnaire (English) 
Please answer the following questions about your college experience truthfully.  
Stimulants refer to prescription medications including methylphenidate (Ritalin, 
Concerta, Metadate) and amphetamine (Adderall, Dexedrine, Desoxyn). 
 
Please circle the number that best describes your agreement with each statement. 
These questions are rated on a Likert scale:              Never    Rarely  Occasionally  Frequently  Always 
1.   I have used prescription stimulants for non-medical purposes. 1              2                3                   4                5    
  
2.   I have used prescription stimulants at parties.            1              2                3                   4                5        
3.   I have used prescription stimulants with alcohol.           1              2                3                   4                5     
4.   I have snorted prescription stimulants.            1              2                3                   4                5               
5.   I have injected prescription stimulants.            1              2                3                   4                5     
6.   I have smoked prescription stimulants.            1              2                3                   4                5     
7.   I have taken prescription stimulants to focus better in class.     1              2                3                   4                 5   
8.   I have taken prescription stimulants to perform better on tests. 1              2                3                   4                5     
9.   I have taken prescription stimulants to help me socialize better.1             2                3                   4                5  
10. I have taken prescription stimulants to help me lose weight.     1              2                3                   4                5     
11. I have taken prescription stimulants to perform           1              2                3                   4                5                                     
better in my school work. 
12. I have taken prescription stimulants to feel more energetic.       1              2                3                   4                5     
13. I have taken prescription stimulants to feel better about myself.1              2                3                   4                5     
14. I have taken prescription stimulants to “get high”.             1              2                3                   4                5  
15. I have been offered prescription stimulants by other students.   1              2                3                   4                5 
16. I have tried someone else’s prescription stimulant medication.  1              2                3                   4                5                
17. I have purchased prescription stimulants from other students.    1              2                3                   4                5                 
18. I have sold prescription stimulant medication to other students. 1              2                3                   4                5                 
19. I have given prescription stimulant medication to other students.1              2                3                   4                5                     
20. I have been pressured into letting someone else                           1              2                3                   4                5    
      have my  prescription stimulant medication.                          
            
Please answer the following questions about your college experience truthfully.  
Stimulants refer to prescription medications including methylphenidate (Ritalin, 
Concerta, Metadate) and amphetamine (Adderall, Dexedrine, Desoxyn). 
 
Please circle the number that best describes your agreement with each statement. 
        Strongly                           Strongly 
These questions are rated on a Likert scale:                            Disagree       Disagree    Neutral    Agree          Agree 
21. Prescription stimulants are easy to get on this campus.        1               2  3     4       5 
22. Prescription stimulants are as easy to get as alcohol.        1               2  3     4       5 
23. Prescription stimulants are as easy to get as marijuana.        1               2  3     4       5 
24. Using prescription stimulants occasionally is harmless.        1               2  3     4       5 
25. Using prescription stimulants daily is harmless.        1               2  3     4       5 
26. Prescription stimulant use on campus is a problem.        1               2  3     4       5 
27. Prescription stimulants are safer than marijuana.        1               2  3     4       5 
28. Prescription stimulants are safer than alcohol.         1               2  3     4       5 
29. I feel I am knowledgeable about prescription stimulants.       1               2  3     4       5 
30. I feel I am knowledgeable about the side effects        1               2  3     4       5 
of prescription stimulants.  
 
Please Circle Yes or No to the following questions: 
31. I know students who use prescription stimulants at parties.   YES        NO  
32. I know students who use prescription stimulants with alcohol.   YES        NO 
33. I know students who use prescription stimulants with other drugs.   YES        NO 
34. I know students who use prescription stimulants while studying.                       YES        NO 
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35. I know students who use prescription stimulants during finals week.  YES       NO  
36. I know students who use prescription stimulants during tests.   YES       NO  
37. I know students who snort prescription stimulants.    YES       NO 
38. I know students who inject prescription stimulants.    YES       NO  
39. I know students who smoke prescription stimulants.    YES       NO  
40. I hide my prescription stimulant medication so that no one will take it.  YES         NO 
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Appendix G (continued) 
 
Stimulant Survey Questionnaire (Icelandic) 
Vinsamlega svaraðu eftirfarandi spurningum hreinskilnislega. Miðað er við tímabilið frá því 
háskólanám hófst. Þegar talað er um“örvandi lyfseðilsskyld lyf” er átt við lyf sem ávísað er 
með lyfseðli, svo sem metýlfenídat, t.d. Ritalin, Ritalin-Uno, Concerta og skyld lyf (t.d. 
Adderall, Vyvanse, Focalin o.fl.). 
 
Vinsamlega veldu það svar sem á best við hverju sinni. 
                      Aldrei    Sjaldan    Stundum    Oft        Alltaf 
1.   Ég hef notað örvandi lyfseðilsskyld lyf í öðrum       1               2                 3            4              5 
tilgangi en læknisfræðilegum.  
2.   Ég hef notað örvandi lyf þegar ég fer út að skemmta   1               2                 3            4              5 
mér eða “á djamminu”. 
3.   Ég hef notað örvandi lyfseðilsskyld lyf með áfengi.    1               2                 3            4              5     
4.   Ég hef sniffað/snortað/sogið örvandi lyfseðilsskyld     1              2                  3            4              5 
lyf gegnum nefið. 
5.   Ég hef sprautað mig með örvandi lyfseðilsskyldum     1              2                  3            4              5 
lyfjum.  
6.   Ég hef reykt örvandi lyfseðilsskyld lyf.        1              2                  3               4              5     
7.   Ég hef tekið örvandi lyfseðilsskyld lyf til auka       1              2                  3               4              5 
einbeitingu mína í tíma.  
8.   Ég hef tekið örvandi lyfseðilsskyld lyf til að                1              2                  3               4              5 
standa mig betur á prófum. 
9.   Ég hef tekið örvandi lyfseðilsskyld lyf til að eiga       1              2                  3               4              5 
auðveldara með samskipti við aðra.     
10. Ég hef tekið örvandi lyfseðilsskyld lyf til að        1              2                  3               4              5 
 grennast. 
11. Ég hef tekið örvandi lyfseðilsskyld lyf til að       1              2                  3               4              5 
 standa mig betur í námi 
12. Ég hef tekið örvandi lyfseðilsskyld lyf til að       1              2                  3               4              5 
fá aukaorku. 
13. Ég hef tekið örvandi lyfseðilsskyld lyf til að       1              2                  3               4              5 
bæta sjálfsálit mitt.  
14. Ég hef tekið örvandi lyfseðilsskyld lyf til þess       1              2                  3               4              5   
að komast í vímu. 
15. Aðrir nemendur hafa boðið mér örvandi        1              2                  3               4              5 
lyfseðilsskyld lyf. 
16. Ég hef prófað örvandi lyfseðilsskyld lyf af       1              2                  3               4              5 
 öðrum nemendum. 
17. Ég hef keypt örvandi lyfseðilsskyld lyf af       1              2                  3               4              5 
 öðrum nemendum. 
18. Ég hef selt öðrum nemendum örvandi        1              2                  3               4              5 
 lyfseðilsskyld lyf. 
19. Ég hef gefið öðrum nemendum örvandi        1              2                  3               4              5 
 lyfseðilsskyld lyf. 
20. Ég hef orðið fyrir þrýstingi að gefa öðrum                   1              2                  3               4              5 
örvandi lyf sem ávísað var til mín. 
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Vinsamlega svaraðu eftirfarandi spurningum hreinskilnislega.Þegar talað er um“örvandi lyf” 
er átt við lyf sem ávísað er með lyfseðli, þ.m.t. metýlfenídat, t.d. Ritalin, Ritalin-Uno, Concerta 
og skyld lyf (t.d. Adderall, Vyvanse, Focalin o.fl.). 
 
Vinsamlega veldu það svar sem á best við hverju sinni. 
 
              Mjög                 Mjög 
    Ósammála Ósammála Hvorki/né Sammála Sammála 
21. Það er auðvelt að verða sér úti um örvandi 1   2   3     4       5 
lyfseðilsskyld lyf  í háskólasamfélaginu. 
22. Það er jafnauðvelt að verða sér úti um   1   2   3     4       5 
örvandi lyfseðilsskyld lyf og áfengi. 
23. Það er jafnauðvelt að verða sér úti um örvandi      1   2   3     4       5 
lyfseðilsskyld lyf og gras/marijúana 
24. Það er óhætt að nota örvandi   1   2   3     4       5 
lyfseðilsskyld lyf af og til. 
25. Það er óhætt að nota örvandi   1   2   3     4       5 
lyfseðilsskyld lyf daglega. 
26. Notkun örvandi lyfseðilsskyldra lyfja er   1   2   3     4       5 
vandamál í háskólasamfélaginu. 
27. Örvandi lyfseðilsskyld lyf eru öruggari en 1   2   3     4       5 
marijúana.  
28. Örvandi lyfseðilsskyld lyf eru öruggari en áfengi. 1   2   3     4       5 
29. Ég tel mig vel upplýsta/-n um örvandi  1   2   3     4       5 
lyfseðilsskyld lyf. 
30. Ég tel mig vel upplýsta/-n um aukaverkanir 1   2   3     4       5 
örvandilyfseðilsskyldra lyfja. 
 
Vinsamlega veldu JÁ eða NEI eftir því sem við á: 
 
31. Ég veit um nemendur sem nota örvandi lyfseðilsskyld lyf þegar þeir   JÁ        NEI 
fara út að skemmta sér. 
32. Ég veit um nemendur sem nota örvandi lyfseðilsskyld lyf með áfengi.  JÁ        NEI 
33. Ég veit um nemendur sem nota örvandi lyfseðilsskyld lyf með öðrum lyfjum. JÁ        NEI 
34. Ég veit um nemendur sem nota örvandi lyfseðilsskyld lyf þegar þeir læra.       JÁ        NEI 
  
35. Ég veit um nemendur sem nota örvandi lyfseðilsskyld lyf í prófum.   JÁ       NEI  
36. Ég veit um nemendur sem taka örvandi lyfseðilsskyld lyf (snorta/sniffa)  JÁ NEI 
í nefið. 
37. Ég veit um nemendur sem sprauta sig með örvandi lyfseðilsskyldum lyfjum.  JÁ       NEI  
38. Ég veit um nemendur sem reykja örvandi lyfseðilsskyld lyf.   JÁ       NEI 
39. Ég fel örvandi lyfseðilsskyld lyf sem var ávísað til mín fyrir öðrum   JÁ         NEI 
svo enginn taki þau. 
 
 
 
